Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Leukemia

Retrieve available abstracts of 588 articles:
HTML format

Single Articles

    May 2024
  1. GALE RP, Hochhaus A
    To Mars and beyond. Space exploration and space medicine in Leukemia.
    Leukemia. 2024 May 22. doi: 10.1038/s41375-024-02286.

    Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries.
    Leukemia. 2024 May 18. doi: 10.1038/s41375-024-02277.
    PubMed     Abstract available

  3. CORTES JE, Sasaki K, Kim DW, Hughes TP, et al
    Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after >/=1 prior tyrosine kinase inhibitor: 2-year follow-up results.
    Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02278.
    PubMed     Abstract available

  4. MALCIKOVA J, Pavlova S, Baliakas P, Chatzikonstantinou T, et al
    ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.
    Leukemia. 2024 May 16. doi: 10.1038/s41375-024-02267.
    PubMed     Abstract available

  5. NEUMANN M, Beder T, Bastian L, Hanzelmann S, et al
    Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.
    Leukemia. 2024 May 14. doi: 10.1038/s41375-024-02264.
    PubMed     Abstract available

  6. KARAMI A, Skorski T
    DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02269.

  7. AWADA H, Durmaz A, Kewan T, Ullah F, et al
    Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02268.

  8. MORII M, Kubota S, Iimori M, Yokomizo-Nakano T, et al
    TIF1beta activates leukemic transcriptional program in HSCs and promotes BCR::ABL1-induced myeloid leukemia.
    Leukemia. 2024 May 11. doi: 10.1038/s41375-024-02276.
    PubMed     Abstract available

  9. O'CONNOR KW, Kishimoto K, Kuzma IO, Wagner KP, et al
    The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance.
    Leukemia. 2024;38:951-962.
    PubMed     Abstract available

  10. SRINIVASAN S, Keerthivasagam S
    Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights.
    Leukemia. 2024;38:1187-1188.

  11. SCHULTZ LM, Jeyakumar N, Kramer AM, Sahaf B, et al
    CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
    Leukemia. 2024;38:963-968.
    PubMed     Abstract available

  12. WONG JC, Weinfurtner KM, Westover T, Kim J, et al
    5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
    Leukemia. 2024;38:1182-1186.
    PubMed     Abstract available

  13. YI W, Zhang J, Huang Y, Zhan Q, et al
    Ferritin-mediated mitochondrial iron homeostasis is essential for the survival of hematopoietic stem cells and leukemic stem cells.
    Leukemia. 2024;38:1003-1018.
    PubMed     Abstract available

    April 2024
  14. GUO J, Buettner R, Du L, Li Z, et al
    8-Cl-Ado and 8-NH(2)-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia.
    Leukemia. 2024 Apr 20. doi: 10.1038/s41375-024-02222.
    PubMed     Abstract available

  15. IYODA S, Yoshida K, Shoji K, Ito N, et al
    KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
    Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02244.

  16. NORONHA N, Durette C, Cahuzac M, E Silva B, et al
    Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia.
    Leukemia. 2024 Apr 16. doi: 10.1038/s41375-024-02250.
    PubMed     Abstract available

  17. CURIK N, Laznicka A, Polivkova V, Krizkova J, et al
    Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
    Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248.

  18. MATSUI S, Ri C, Bolanos LC, Choi K, et al
    Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.
    Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245.
    PubMed     Abstract available

  19. BELL HL, Blair HJ, Jepson Gosling SJ, Galler M, et al
    Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
    Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02241.
    PubMed     Abstract available

  20. FRUCHTMAN H, Avigan ZM, Waksal JA, Brennan N, et al
    Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
    Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02246.
    PubMed     Abstract available

  21. BORDINI J, Lenzi C, Frenquelli M, Morabito A, et al
    IkappaBepsilon deficiency accelerates disease development in chronic lymphocytic leukemia.
    Leukemia. 2024 Apr 4. doi: 10.1038/s41375-024-02236.
    PubMed     Abstract available

  22. MCLORNAN DP, Czerw T, Damaj G, Ethell M, et al
    Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
    Leukemia. 2024;38:699-711.
    PubMed     Abstract available

  23. LUBKE J, Christen D, Schwaab J, Kaiser A, et al
    Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
    Leukemia. 2024;38:810-821.
    PubMed     Abstract available

  24. SHIMONY S, Bewersdorf JP, Shallis RM, Liu Y, et al
    Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
    Leukemia. 2024;38:762-768.
    PubMed     Abstract available

  25. SEBERT M, Freiman L, Chaffaut C, Guerci A, et al
    Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
    Leukemia. 2024;38:918-922.

  26. SEVERENS JF, Karakaslar EO, van der Reijden BA, Sanchez-Lopez E, et al
    Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
    Leukemia. 2024;38:751-761.
    PubMed     Abstract available

    March 2024
  27. JASSINSKAJA M, Ghosh S, Watral J, Davoudi M, et al
    A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia.
    Leukemia. 2024 Mar 30. doi: 10.1038/s41375-024-02235.
    PubMed     Abstract available

  28. BRIOLI A, Lomaia E, Fabisch C, Sacha T, et al
    Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
    Leukemia. 2024 Mar 28. doi: 10.1038/s41375-024-02204.
    PubMed     Abstract available

  29. DE CAMARGO MAGALHAES ES, Hubner SE, Brown BD, Qiu Y, et al
    Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
    Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02208.
    PubMed     Abstract available

  30. KANTARJIAN H, Branford S, Breccia M, Cortes J, et al
    Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?
    Leukemia. 2024 Mar 26. doi: 10.1038/s41375-024-02229.

  31. BURMEISTER T, Stroh AS, Kehden B, Trautmann H, et al
    Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
    Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209.

  32. FARROKHI A, Atre T, Rever J, Fidanza M, et al
    The Emu-Ret mouse is a novel model of hyperdiploid B-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02221.
    PubMed     Abstract available

  33. BONATO A, Chakraborty S, Bomben R, Canarutto G, et al
    NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.
    Leukemia. 2024 Mar 15. doi: 10.1038/s41375-024-02224.
    PubMed     Abstract available

  34. ZACKOVA D, Semerad L, Faber E, Klamova H, et al
    Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
    Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215.

  35. SCHWEDE M, Jahn K, Kuipers J, Miles LA, et al
    Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity.
    Leukemia. 2024 Mar 11. doi: 10.1038/s41375-024-02211.
    PubMed     Abstract available

  36. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
    Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
    Leukemia. 2024 Mar 8. doi: 10.1038/s41375-024-02202.

  37. THOMAS ME 3RD, Qi W, Walsh MP, Ma J, et al
    Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia.
    Leukemia. 2024 Mar 7. doi: 10.1038/s41375-024-02193.
    PubMed     Abstract available

  38. PERUSINI MA, Andrews C, Eshetu AG, Gupta V, et al
    Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol.
    Leukemia. 2024 Mar 2. doi: 10.1038/s41375-024-02201.

  39. MA J, Liu YC, Voss RK, Ma J, et al
    Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion.
    Leukemia. 2024 Mar 1. doi: 10.1038/s41375-024-02194.
    PubMed     Abstract available

  40. CHEN CC, Silberman RE, Ma D, Perry JA, et al
    Inherent genome instability underlies trisomy 21-associated myeloid malignancies.
    Leukemia. 2024;38:521-529.
    PubMed     Abstract available

  41. SANZ-ORTEGA L, Andersson A, Carlsten M
    Harnessing upregulated E-selectin while enhancing SDF-1alpha sensing redirects infused NK cells to the AML-perturbed bone marrow.
    Leukemia. 2024;38:579-589.
    PubMed     Abstract available

  42. PARRIOTT G, Hegermiller E, Morman RE, Frank C, et al
    Loss of thymocyte competition underlies the tumor suppressive functions of the E2a transcription factor in T-ALL.
    Leukemia. 2024;38:491-501.
    PubMed     Abstract available

  43. SPINELLA JF, Chagraoui J, Moison C, Lavallee VP, et al
    DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML.
    Leukemia. 2024;38:530-537.
    PubMed     Abstract available

  44. BIRDWELL CE, Fiskus W, Kadia TM, Mill CP, et al
    Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
    Leukemia. 2024;38:545-556.
    PubMed     Abstract available

    February 2024
  45. CLAUDIANI S, Chughtai F, Khan A, Hayden C, et al
    Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance.
    Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02187.
    PubMed     Abstract available

  46. YANG X, Liu J, Liu W, Wu H, et al
    circFAM193B interaction with PRMT6 regulates AML leukemia stem cells chemoresistance through altering the oxidative metabolism and lipid peroxidation.
    Leukemia. 2024 Feb 29. doi: 10.1038/s41375-024-02189.
    PubMed     Abstract available

  47. FLYGT H, Soderlund S, Richter J, Saussele S, et al
    Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
    Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02184.

  48. MONTALBAN-BRAVO G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, et al
    Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
    Leukemia. 2024 Feb 28. doi: 10.1038/s41375-024-02190.

  49. JUNK SV, Forster A, Schmidt G, Zimmermann M, et al
    Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia-a case-control study.
    Leukemia. 2024 Feb 27. doi: 10.1038/s41375-024-02173.

  50. CHELYSHEVA E, Apperley J, Turkina A, Yassin MA, et al
    Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry.
    Leukemia. 2024 Feb 23. doi: 10.1038/s41375-024-02183.
    PubMed     Abstract available

  51. OLIVIERI DJ, Othus M, Orvain C, Rodriguez-Arboli E, et al
    Impact of socioeconomic disparities on outcomes in adults undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Leukemia. 2024 Feb 22. doi: 10.1038/s41375-024-02172.
    PubMed     Abstract available

  52. AVENARIUS MR, Huang Y, Kittai AS, Bhat SA, et al
    Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia.
    Leukemia. 2024 Feb 19. doi: 10.1038/s41375-024-02177.

  53. CHATZIKONSTANTINOU T, Agathangelidis A, Chatzidimitriou A, Tresoldi C, et al
    Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia.
    Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02163.

  54. LIN S, Schneider C, Su AH, Alexe G, et al
    The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response to venetoclax in acute myeloid leukemia.
    Leukemia. 2024 Feb 16. doi: 10.1038/s41375-024-02178.

  55. DELROCCO NJ, Loh ML, Borowitz MJ, Gupta S, et al
    Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.
    Leukemia. 2024 Feb 15. doi: 10.1038/s41375-024-02166.
    PubMed     Abstract available

  56. LI Y, Mendoza-Castrejon J, Patel RM, Casey EB, et al
    LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression.
    Leukemia. 2024 Feb 6. doi: 10.1038/s41375-024-02167.

  57. FRANKHOUSER DE, Rockne RC, Uechi L, Zhao D, et al
    State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia.
    Leukemia. 2024 Feb 2. doi: 10.1038/s41375-024-02142.
    PubMed     Abstract available

  58. KLYUCHNIKOV E, Badbaran A, Massoud R, Freiberger P, et al
    Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.
    Leukemia. 2024;38:386-388.

  59. ELDEEB M, Konturek-Ciesla A, Zhang Q, Kharazi S, et al
    Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell self-renewal and disrupt early lymphopoiesis.
    Leukemia. 2024;38:455-459.

  60. GEORGI JA, Stasik S, Kramer M, Meggendorfer M, et al
    Prognostic impact of CEBPA mutational subgroups in adult AML.
    Leukemia. 2024;38:281-290.
    PubMed     Abstract available

  61. HEHLMANN R, Lauseker M
    How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies.
    Leukemia. 2024;38:465-466.

  62. CHEN J, Gale RP
    Response to Pfirrmann et al.'s comment on How should we interpret conclusions of TKI-stopping studies.
    Leukemia. 2024;38:463-464.

  63. LEE KH, Lee S, Park YH, Mun YC, et al
    Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis.
    Leukemia. 2024;38:451-454.

  64. MATTANO LA JR, Devidas M, Loh ML, Raetz EA, et al
    Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232.
    Leukemia. 2024;38:258-265.
    PubMed     Abstract available

  65. CHEN Y, Wen J, Li Q, Peng D, et al
    RAB27B-regulated exosomes mediate LSC maintenance via resistance to senescence and crosstalk with the microenvironment.
    Leukemia. 2024;38:266-280.
    PubMed     Abstract available

  66. SUI P, Ge G, Chen S, Bai J, et al
    SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis.
    Leukemia. 2024;38:408-411.

    January 2024
  67. DAM M, Centanni M, Friberg LE, Centanni D, et al
    Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia.
    Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02153.
    PubMed     Abstract available

  68. JABBOUR E, Apperley J, Cortes J, Rea D, et al
    Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
    Leukemia. 2024 Jan 29. doi: 10.1038/s41375-024-02159.
    PubMed     Abstract available

  69. FLYGT H, Soderlund S, Richter J, Saussele S, et al
    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
    Leukemia. 2024 Jan 26. doi: 10.1038/s41375-024-02145.
    PubMed     Abstract available

  70. TAN SH, Tan TK, Yokomori R, Liao M, et al
    Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
    Leukemia. 2024 Jan 25. doi: 10.1038/s41375-023-02125.

  71. TETTERO JM, Heidinga ME, Mocking TR, Fransen G, et al
    Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
    Leukemia. 2024 Jan 25. doi: 10.1038/s41375-024-02158.
    PubMed     Abstract available

  72. APPELBAUM JS, Wei AH, Mandrekar SJ, Tiong IS, et al
    Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
    Leukemia. 2024 Jan 23. doi: 10.1038/s41375-024-02143.

  73. KANG H, Hoang DH, Valerio M, Pathak K, et al
    OST-01, a natural product from Baccharis coridifolia, targets c-Myc-dependent ribogenesis in acute myeloid leukemia.
    Leukemia. 2024 Jan 17. doi: 10.1038/s41375-024-02146.

  74. TOMA MM, Karami A, Nieborowska-Skorska M, Chirtala KN, et al
    Clonal medicine targeting DNA damage response eradicates leukemia.
    Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02138.

  75. CHEN DW, Fan JM, Schrey JM, Mitchell DV, et al
    Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche.
    Leukemia. 2024 Jan 16. doi: 10.1038/s41375-024-02136.
    PubMed     Abstract available

  76. HANEL G, Schonle A, Neumann AS, Nixdorf D, et al
    Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
    Leukemia. 2024 Jan 11. doi: 10.1038/s41375-023-02127.

  77. VALTIS YK, Flamand Y, Shimony S, Place AE, et al
    Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.
    Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02115.
    PubMed     Abstract available

  78. SUNG PJ, Selvam M, Riedel SS, Xie HM, et al
    FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
    Leukemia. 2024 Jan 5. doi: 10.1038/s41375-023-02131.
    PubMed     Abstract available

  79. POTLURI S, Kellaway SG, Coleman DJL, Keane P, et al
    Gene regulation in t(6;9) DEK::NUP214 Acute Myeloid Leukemia resembles that of FLT3-ITD/NPM1 Acute Myeloid Leukemia but with an altered HOX/MEIS axis.
    Leukemia. 2024 Jan 4. doi: 10.1038/s41375-023-02118.

    Quantifying measurable residual disease correctly.
    Leukemia. 2024;38:221-222.

  81. TYAGI A, Jaggupilli A, Ly S, Yuan B, et al
    TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
    Leukemia. 2024;38:82-95.
    PubMed     Abstract available

  82. ZHOU YL, Zhao MY, Gale RP, Jiang H, et al
    Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics.
    Leukemia. 2024;38:223-225.

  83. CHEN J
    Response to comment on Have we been qualifying measurable residual disease correctly?
    Leukemia. 2024;38:219-220.

  84. RADIVOYEVITCH T, Gale RP, Kalaycio ME
    What do atomic bomb survivors teach us about therapy-free remission in people with chronic myeloid leukaemia?
    Leukemia. 2024;38:207-209.

  85. GARCIA-MANERO G, Podoltsev NA, Othus M, Pagel JM, et al
    A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
    Leukemia. 2024;38:58-66.
    PubMed     Abstract available

  86. YAN M, Liu M, Davis AG, Stoner SA, et al
    Single-cell RNA sequencing of a new transgenic t(8;21) preleukemia mouse model reveals regulatory networks promoting leukemic transformation.
    Leukemia. 2024;38:31-44.
    PubMed     Abstract available

    December 2023
  87. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
    Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
    Leukemia. 2023 Dec 26. doi: 10.1038/s41375-023-02117.
    PubMed     Abstract available

  88. YANADA M, Yamasaki S, Kondo T, Kawata T, et al
    Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission.
    Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02119.
    PubMed     Abstract available

  89. MACHOVA POLAKOVA K, Albeer A, Polivkova V, Krutska M, et al
    The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
    Leukemia. 2023 Dec 21. doi: 10.1038/s41375-023-02109.
    PubMed     Abstract available

  90. DE SMITH AJ, Wiemels JL, Mead AJ, Roberts I, et al
    Backtracking to the future: unraveling the origins of childhood leukemia.
    Leukemia. 2023 Dec 20. doi: 10.1038/s41375-023-02111.

  91. FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
    Correction: A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
    Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02112.

  92. MURPHY T, Mason JM, Leber B, Bray MR, et al
    Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
    Leukemia. 2023 Dec 19. doi: 10.1038/s41375-023-02110.
    PubMed     Abstract available

  93. HOFFMEISTER LM, Suttorp J, Walter C, Antoniou E, et al
    Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia.
    Leukemia. 2023 Dec 12. doi: 10.1038/s41375-023-02102.
    PubMed     Abstract available

  94. KOVTUN I, von Bonin M, Ibneeva L, Frimmel J, et al
    Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia.
    Leukemia. 2023 Dec 8. doi: 10.1038/s41375-023-02104.

  95. TANNOURY M, Ayoub M, Dehgane L, Nemazanyy I, et al
    ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia.
    Leukemia. 2023 Dec 6. doi: 10.1038/s41375-023-02103.
    PubMed     Abstract available

  96. SABA L, Landau KS, Liang H, Fu CL, et al
    Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States.
    Leukemia. 2023 Dec 4. doi: 10.1038/s41375-023-02100.

  97. ANTIC Z, van Bommel A, Riege K, Lentes J, et al
    Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALL.
    Leukemia. 2023;37:2522-2525.

    Glasdigib fails to slay the hedgehog in pivotal AML trials.
    Leukemia. 2023;37:2520-2521.

  99. BOUCHLA A, Papageorgiou SG, Symeonidis A, Sakellari I, et al
    Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?
    Leukemia. 2023;37:2517-2519.

  100. XIANG J, Devenport JM, Carter AJ, Staser KW, et al
    An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
    Leukemia. 2023;37:2448-2456.
    PubMed     Abstract available

    November 2023
  101. MILIARA S, Cozzi E, Zhong X, Chan I, et al
    The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia.
    Leukemia. 2023 Nov 30. doi: 10.1038/s41375-023-02098.

  102. PLAYA-ALBINYANA H, Arenas F, Royo R, Giro A, et al
    Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
    Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02095.
    PubMed     Abstract available

  103. OZGA M, Nicolet D, Mrozek K, Yilmaz AS, et al
    Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
    Leukemia. 2023 Nov 28. doi: 10.1038/s41375-023-02068.
    PubMed     Abstract available

  104. ROSTI G, Brummendorf TH, Gjertsen BT, Giraldo-Castellano P, et al
    Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.
    Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02080.
    PubMed     Abstract available

  105. FIJALKOWSKI I, Wang J, Jin Q, Van Laere J, et al
    A positive feedback loop regulation between NOTCH1 and USP11 in T-cell leukemia.
    Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02096.

  106. LEUNG KT, Cai J, Liu Y, Chan KYY, et al
    Prognostic implications of CD9 in childhood acute lymphoblastic leukemia: insights from a nationwide multicenter study in China.
    Leukemia. 2023 Nov 25. doi: 10.1038/s41375-023-02089.
    PubMed     Abstract available

  107. ZALIOVA M, Zuna J, Winkowska L, Janotova I, et al
    Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
    Leukemia. 2023 Nov 24. doi: 10.1038/s41375-023-02083.
    PubMed     Abstract available

  108. WALTER RB
    Perspective on measurable residual disease testing in acute myeloid leukemia.
    Leukemia. 2023 Nov 16. doi: 10.1038/s41375-023-02084.

  109. WU Y, Zehnle PMA, Rajak J, Koleci N, et al
    BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
    Leukemia. 2023 Nov 9. doi: 10.1038/s41375-023-02079.
    PubMed     Abstract available

  110. ALSHAMLEH I, Kurrle N, Makowka P, Bhayadia R, et al
    PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.
    Leukemia. 2023 Nov 7. doi: 10.1038/s41375-023-02041.
    PubMed     Abstract available

  111. TOMIZAWA D, Matsubayashi J, Iwamoto S, Hiramatsu H, et al
    High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
    Leukemia. 2023 Nov 6. doi: 10.1038/s41375-023-02075.

  112. HUUHTANEN J, Adnan-Awad S, Theodoropoulos J, Forsten S, et al
    Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
    Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02074.
    PubMed     Abstract available

  113. WEISCHENDORFF S, Rathe M, Petersen MJ, Weimann A, et al
    Markers of intestinal mucositis to predict blood stream infections at the onset of fever during treatment for childhood acute leukemia.
    Leukemia. 2023 Nov 2. doi: 10.1038/s41375-023-02077.
    PubMed     Abstract available

  114. FALINI B, Gjertsen BT, Andresen V
    The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML?
    Leukemia. 2023;37:2173-2175.

  115. LAUSEKER M, Hehlmann R, Hochhaus A, Saussele S, et al
    Survival with chronic myeloid leukaemia after failing milestones.
    Leukemia. 2023;37:2231-2236.
    PubMed     Abstract available

  116. DU W, Xia Z, Luo Z, Chen Y, et al
    A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML.
    Leukemia. 2023;37:2286-2291.

  117. BUROCZIOVA M, Danek P, Oravetzova A, Chalupova Z, et al
    Ppm1d truncating mutations promote the development of genotoxic stress-induced AML.
    Leukemia. 2023;37:2209-2220.
    PubMed     Abstract available

  118. FENG Y, Qi S, Liu X, Zhang L, et al
    Have we been qualifying measurable residual disease correctly?
    Leukemia. 2023;37:2168-2172.

  119. LI S, Wang X, Liu L, Liu J, et al
    CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.
    Leukemia. 2023;37:2176-2186.
    PubMed     Abstract available

    October 2023
  120. CERELLA C, Gajulapalli SR, Lorant A, Gerard D, et al
    ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.
    Leukemia. 2023 Oct 30. doi: 10.1038/s41375-023-02076.
    PubMed     Abstract available

  121. BISCHOF L, Ussmann J, Grimm J, Bill M, et al
    Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02072.

  122. V STACKELBERG A, Jaschke K, Jousseaume E, Templin C, et al
    Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2023 Oct 25. doi: 10.1038/s41375-023-02042.
    PubMed     Abstract available

  123. WU A, Yen R, Grasedieck S, Lin H, et al
    Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.
    Leukemia. 2023 Oct 17. doi: 10.1038/s41375-023-02062.
    PubMed     Abstract available

  124. JOHANSSON KB, Zimmerman MS, Dmytrenko IV, Gao F, et al
    Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia.
    Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02057.
    PubMed     Abstract available

  125. DEL GIUDICE I, Foa R
    Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?
    Leukemia. 2023 Oct 14. doi: 10.1038/s41375-023-02066.

  126. ECKARDT JN, Stasik S, Rollig C, Petzold A, et al
    Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
    Leukemia. 2023 Oct 13. doi: 10.1038/s41375-023-02061.
    PubMed     Abstract available

  127. OTTONE T, Silvestrini G, Piazza R, Travaglini S, et al
    Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways.
    Leukemia. 2023 Oct 6. doi: 10.1038/s41375-023-02054.
    PubMed     Abstract available

    What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia.
    Leukemia. 2023 Oct 5. doi: 10.1038/s41375-023-02053.

  129. TULKENS D, Boelens M, Naert T, Carron M, et al
    Mutations in the histone methyltransferase Ezh2 drive context-dependent leukemia in Xenopus tropicalis.
    Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02052.
    PubMed     Abstract available

  130. CROSS NCP, Ernst T, Branford S, Cayuela JM, et al
    European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.
    Leukemia. 2023 Oct 4. doi: 10.1038/s41375-023-02048.
    PubMed     Abstract available

  131. JAHN E, Saadati M, Fenaux P, Gobbi M, et al
    Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
    Leukemia. 2023 Oct 3. doi: 10.1038/s41375-023-02017.

  132. HUBER S, Baer C, Hutter S, Dicker F, et al
    Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.
    Leukemia. 2023;37:2138-2141.

  133. OTHMAN J, Potter N, Mokretar K, Taussig D, et al
    FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
    Leukemia. 2023;37:2066-2072.
    PubMed     Abstract available

  134. FISHER JG, Doyle ADP, Graham LV, Sonar S, et al
    XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
    Leukemia. 2023;37:2036-2049.
    PubMed     Abstract available

  135. CASERTA C, Nucera S, Barcella M, Fazio G, et al
    miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease.
    Leukemia. 2023;37:1994-2005.
    PubMed     Abstract available

  136. TIAN Z, Shi C, Yang G, Allen JK, et al
    Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.
    Leukemia. 2023;37:2006-2016.
    PubMed     Abstract available

  137. GURULE NJ, Malcolm KC, Harris C, Knapp JR, et al
    Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
    Leukemia. 2023;37:2115-2124.
    PubMed     Abstract available

    September 2023
  138. MALIK N, Hay J, Almuhanna HNB, Dunn KM, et al
    mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia.
    Leukemia. 2023 Sep 29. doi: 10.1038/s41375-023-02043.
    PubMed     Abstract available

  139. JONDREVILLE L, Dehgane L, Doualle C, Smagghe L, et al
    del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia.
    Leukemia. 2023 Sep 26. doi: 10.1038/s41375-023-02035.
    PubMed     Abstract available

  140. FECHINA L, Popov A, Tsaur G, Henze G, et al
    Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
    Leukemia. 2023 Sep 23. doi: 10.1038/s41375-023-02034.

  141. KUBASCH AS, Peterlin P, Cluzeau T, Gotze KS, et al
    Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
    Leukemia. 2023 Sep 21. doi: 10.1038/s41375-023-02029.

  142. DOBISH KK, Wittorf KJ, Swenson SA, Bean DC, et al
    FBXO21 mediated degradation of p85alpha regulates proliferation and survival of acute myeloid leukemia.
    Leukemia. 2023 Sep 9. doi: 10.1038/s41375-023-02020.
    PubMed     Abstract available

  143. ECKARDT JN, Bill M, Rausch C, Metzeler K, et al
    Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification.
    Leukemia. 2023 Sep 7. doi: 10.1038/s41375-023-02016.

  144. ZHAO LP, Fenaux P
    What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?
    Leukemia. 2023;37:1943.

  145. GARCIA-CUELLAR MP, Akan S, Slany RK
    A C/ebpalpha isoform specific differentiation program in immortalized myelocytes.
    Leukemia. 2023;37:1850-1859.
    PubMed     Abstract available

  146. QI F, Zhang X, Gale RP, Liu B, et al
    External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy.
    Leukemia. 2023;37:1922-1924.

  147. FLOISAND Y, Remberger M, Bigalke I, Josefsen D, et al
    WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy.
    Leukemia. 2023;37:1842-1849.
    PubMed     Abstract available

  148. PALAU A, Segerberg F, Lidschreiber M, Lidschreiber K, et al
    Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells.
    Leukemia. 2023;37:1830-1841.
    PubMed     Abstract available

  149. TANAKA A, Nishimura K, Saika W, Kon A, et al
    SETBP1 is dispensable for normal and malignant hematopoiesis.
    Leukemia. 2023;37:1802-1811.
    PubMed     Abstract available

  150. NELDEBORG S, Soerensen JF, Moller CT, Bill M, et al
    Dual intron-targeted CRISPR-Cas9-mediated disruption of the AML RUNX1-RUNX1T1 fusion gene effectively inhibits proliferation and decreases tumor volume in vitro and in vivo.
    Leukemia. 2023;37:1792-1801.
    PubMed     Abstract available

  151. CESARO S, Mikulska M, Hirsch HH, Styczynski J, et al
    Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9).
    Leukemia. 2023;37:1933-1938.

    August 2023
  152. SEKERES MA, Montesinos P, Novak J, Wang J, et al
    Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
    Leukemia. 2023 Aug 21. doi: 10.1038/s41375-023-02001.
    PubMed     Abstract available

  153. TAN SH, Tan TK, Yokomori R, Liao M, et al
    TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
    Leukemia. 2023 Aug 17. doi: 10.1038/s41375-023-01993.
    PubMed     Abstract available

  154. JAHN E, Saadati M, Fenaux P, Gobbi M, et al
    Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
    Leukemia. 2023 Aug 17. doi: 10.1038/s41375-023-01999.
    PubMed     Abstract available

  155. ZHU D, Jiang T, Ma D, Zhang H, et al
    S1P-S1PR3-RAS promotes the progression of S1PR3(hi) TAL1(+) T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist.
    Leukemia. 2023 Aug 17. doi: 10.1038/s41375-023-02000.
    PubMed     Abstract available

  156. EIFERT T, Hsu CJ, Becker AL, Graessle S, et al
    Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia.
    Leukemia. 2023 Aug 16. doi: 10.1038/s41375-023-02005.
    PubMed     Abstract available

  157. JUNG J, Kwag D, Kim Y, Lee JM, et al
    Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest World Health Organization and the International Consensus Classifications.
    Leukemia. 2023 Aug 14. doi: 10.1038/s41375-023-01996.

  158. HOSHITSUKI K, Zhou Y, Miller AM, Choi JK, et al
    Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.
    Leukemia. 2023 Aug 5. doi: 10.1038/s41375-023-01992.
    PubMed     Abstract available

  159. VAN ENGELEN N, Roest M, van Dijk F, Sonneveld E, et al
    A novel germline PAX5 single exon deletion in a pediatric patient with precursor B-cell leukemia.
    Leukemia. 2023 Aug 5. doi: 10.1038/s41375-023-01991.

  160. REINIG EF, Rubinstein JD, Patil AT, Schussman AL, et al
    Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis.
    Leukemia. 2023;37:1589-1599.
    PubMed     Abstract available

  161. JIANG J, Chen J, Liao C, Duan Y, et al
    Inserting EF1alpha-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
    Leukemia. 2023;37:1660-1670.
    PubMed     Abstract available

  162. LOPES BA, Meyer C, Bouzada H, Kulp M, et al
    The recombinome of IKZF1 deletions in B-cell precursor ALL.
    Leukemia. 2023;37:1727-1731.

  163. LAI Q, Hamamoto K, Luo H, Zaroogian Z, et al
    NPM1 mutation reprograms leukemic transcription network via reshaping TAD topology.
    Leukemia. 2023;37:1732-1736.
    PubMed     Abstract available

  164. CATALANO G, Zaza A, Banella C, Pelosi E, et al
    MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs' patients.
    Leukemia. 2023;37:1600-1610.
    PubMed     Abstract available

    July 2023
  165. SHIH L, Othus M, Schonhoff K, Shaw C, et al
    Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms.
    Leukemia. 2023 Jul 31. doi: 10.1038/s41375-023-01981.

  166. HOCHMAN MJ, Othus M, Hasserjian RP, Ambinder A, et al
    Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
    Leukemia. 2023 Jul 31. doi: 10.1038/s41375-023-01985.
    PubMed     Abstract available

  167. HATTORI A, Takamatsu-Ichihara E, Yamamoto Y, Fujita S, et al
    Genetic and chemical targeting of the ATPase complex TIP48 and 49 impairs acute myeloid leukemia.
    Leukemia. 2023 Jul 25. doi: 10.1038/s41375-023-01971.
    PubMed     Abstract available

  168. HENGEVELD PJ, Veelken H, van Bergen CAM, Quinten E, et al
    Prognosis of IGLV3-21(R110) chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.
    Leukemia. 2023 Jul 21. doi: 10.1038/s41375-023-01975.

  169. ALAGGIO R, Amador C, Anagnostopoulos I, Attygalle AD, et al
    Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748.
    Leukemia. 2023 Jul 19. doi: 10.1038/s41375-023-01962.

  170. FANG H, Beird HC, Wang SA, Ibrahim AF, et al
    T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis.
    Leukemia. 2023 Jul 13. doi: 10.1038/s41375-023-01956.

  171. MORALES ML, Garcia-Vicente R, Rodriguez-Garcia A, Reyes-Palomares A, et al
    Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.
    Leukemia. 2023 Jul 8. doi: 10.1038/s41375-023-01963.
    PubMed     Abstract available

  172. GURNEY M, Mangaonkar AA, Lasho T, Finke C, et al
    Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML).
    Leukemia. 2023 Jul 8. doi: 10.1038/s41375-023-01964.

  173. WEIDENAUER K, Schmidt C, Rohde C, Pauli C, et al
    The ribosomal protein S6 kinase alpha-1 (RPS6KA1) induces resistance to venetoclax/azacitidine in acute myeloid leukemia.
    Leukemia. 2023 Jul 6. doi: 10.1038/s41375-023-01951.
    PubMed     Abstract available

  174. HOU S, Wang X, Guo T, Lan Y, et al
    PHF6 maintains acute myeloid leukemia via regulating NF-kappaB signaling pathway.
    Leukemia. 2023 Jul 1. doi: 10.1038/s41375-023-01953.
    PubMed     Abstract available

  175. LIU J, Min S, Kim D, Park J, et al
    Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia.
    Leukemia. 2023 Jul 1. doi: 10.1038/s41375-023-01954.
    PubMed     Abstract available

  176. ISSA H, Bhayadia R, Winkler R, Swart LE, et al
    Preclinical testing of miRNA-193b-3p mimic in acute myeloid leukemias.
    Leukemia. 2023;37:1583-1587.

  177. SANTONI A, Malchiodi M, Zappone E, Sicuranza A, et al
    Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis.
    Leukemia. 2023;37:1580-1582.

  178. SENDKER S, Awada A, Domagalla S, Sendker M, et al
    RUNX1 mutation has no prognostic significance in paediatric AML: a retrospective study of the AML-BFM study group.
    Leukemia. 2023;37:1435-1443.
    PubMed     Abstract available

  179. BRYANT D, Smith L, Rogers-Broadway KR, Karydis L, et al
    Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL.
    Leukemia. 2023;37:1454-1463.
    PubMed     Abstract available

  180. LANGHAMMER M, Schopf J, Jaquet T, Horn K, et al
    Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model.
    Leukemia. 2023;37:1474-1484.
    PubMed     Abstract available

  181. LIU S, Zhou J, Ye X, Chen D, et al
    A novel lncRNA SNHG29 regulates EP300- related histone acetylation modification and inhibits FLT3-ITD AML development.
    Leukemia. 2023;37:1421-1434.
    PubMed     Abstract available

  182. AGUIRRE LE, Al Ali N, Sallman DA, Ball S, et al
    Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
    Leukemia. 2023;37:1530-1539.
    PubMed     Abstract available

  183. THOMPSON PA, Keating MJ, Ferrajoli A, Jain N, et al
    Venetoclax consolidation in high-risk CLL treated with ibrutinib for >/=1 year achieves a high rate of undetectable MRD.
    Leukemia. 2023;37:1444-1453.
    PubMed     Abstract available

  184. DENG S, Du J, Gale RP, Wang L, et al
    Glucose partitioning in the bone marrow micro-environment in acute myeloid leukaemia.
    Leukemia. 2023;37:1407-1412.
    PubMed     Abstract available

  185. HUBER S, Baer C, Hutter S, Dicker F, et al
    AML classification in the year 2023: How to avoid a Babylonian confusion of languages.
    Leukemia. 2023;37:1413-1420.
    PubMed     Abstract available

  186. KUMAR PS, Wiczer T, Rosen L, Pollauf AJ, et al
    Evaluation of bleeding events in patients receiving acalabrutinib therapy.
    Leukemia. 2023;37:1554-1557.

    June 2023
  187. MARION W, Koppe T, Chen CC, Wang D, et al
    RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia.
    Leukemia. 2023 Jun 30. doi: 10.1038/s41375-023-01945.
    PubMed     Abstract available

  188. MAZZERA L, Abeltino M, Lombardi G, Cantoni AM, et al
    MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.
    Leukemia. 2023 Jun 29. doi: 10.1038/s41375-023-01940.
    PubMed     Abstract available

  189. LEW-DERIVRY L, Marceau-Renaut A, Fenwarth L, Cuccuini W, et al
    Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group.
    Leukemia. 2023 Jun 16. doi: 10.1038/s41375-023-01931.

  190. QIAO J, Zhao D, Nguyen LXT, Chen F, et al
    Targeting miR-126 in Ph+ acute lymphoblastic leukemia.
    Leukemia. 2023 Jun 9. doi: 10.1038/s41375-023-01933.

  191. GUARDALUPI F, Sorrentino C, Corradi G, Giancola R, et al
    A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect.
    Leukemia. 2023 Jun 7. doi: 10.1038/s41375-023-01932.

  192. NIXDORF D, Sponheimer M, Berghammer D, Engert F, et al
    Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML.
    Leukemia. 2023;37:1298-1310.
    PubMed     Abstract available

  193. KIELBASSA K, Haselager MV, Bax DJC, van Driel BF, et al
    Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation.
    Leukemia. 2023;37:1268-1276.
    PubMed     Abstract available

  194. SHAO YL, Li YQ, Li MY, Wang LL, et al
    HIF1alpha-mediated transactivation of WTAP promotes AML cell proliferation via m(6)A-dependent stabilization of KDM4B mRNA.
    Leukemia. 2023;37:1254-1267.
    PubMed     Abstract available

  195. ZHAO LP, Sebert M, Mekinian A, Fain O, et al
    What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?
    Leukemia. 2023;37:1186-1190.

  196. MILL CP, Fiskus W, Das K, Davis JA, et al
    Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
    Leukemia. 2023;37:1336-1348.
    PubMed     Abstract available

  197. SCHORE RJ, Angiolillo AL, Kairalla JA, Devidas M, et al
    Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.
    Leukemia. 2023;37:1375-1378.

    May 2023
  198. CHEN Y, Mobius S, Riege K, Hoffmann S, et al
    Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution.
    Leukemia. 2023 May 26. doi: 10.1038/s41375-023-01929.

  199. DIEMER JL, Yu K, Kelly M, Zhen T, et al
    Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing.
    Leukemia. 2023 May 24. doi: 10.1038/s41375-023-01926.

  200. DIAMOND A, Vu L, Bensken WP, Koroukian SM, et al
    Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis.
    Leukemia. 2023 May 23. doi: 10.1038/s41375-023-01915.

  201. NIKITIN E, Kislova M, Morozov D, Belyakova V, et al
    Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
    Leukemia. 2023 May 18. doi: 10.1038/s41375-023-01891.
    PubMed     Abstract available

  202. MATSUKAWA T, Yin M, Nigam N, Negi V, et al
    NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia.
    Leukemia. 2023 May 5. doi: 10.1038/s41375-023-01913.

  203. PASTORET C, Llamas-Gutierrez F, Fouchard M, Moignet A, et al
    Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma.
    Leukemia. 2023 May 4. doi: 10.1038/s41375-023-01922.

  204. GREVE G, Andrieux G, Schlosser P, Blagitko-Dorfs N, et al
    In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts.
    Leukemia. 2023;37:1018-1027.
    PubMed     Abstract available

  205. MEYER C, Larghero P, Almeida Lopes B, Burmeister T, et al
    The KMT2A recombinome of acute leukemias in 2023.
    Leukemia. 2023;37:988-1005.
    PubMed     Abstract available

  206. MASLAH N, Benajiba L, Giraudier S, Kiladjian JJ, et al
    Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.
    Leukemia. 2023;37:957-963.
    PubMed     Abstract available

  207. LU Y, Yang L, Shen M, Zhang Z, et al
    Tespa1 facilitates hematopoietic and leukemic stem cell maintenance by restricting c-Myc degradation.
    Leukemia. 2023;37:1039-1047.
    PubMed     Abstract available

  208. NAKAO F, Setoguchi K, Semba Y, Yamauchi T, et al
    Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance.
    Leukemia. 2023;37:1028-1038.
    PubMed     Abstract available

  209. PUGLIESE GM, Venafra V, Bica V, Massacci G, et al
    Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach.
    Leukemia. 2023;37:1151-1155.

  210. MAURO MJ, Hughes TP, Kim DW, Rea D, et al
    Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
    Leukemia. 2023;37:1048-1059.
    PubMed     Abstract available

  211. WEICHENHAN D, Riedel A, Meinen C, Basic A, et al
    Translocation t(6;7) in AML-M4 cell line GDM-1 results in MNX1 activation through enhancer-hijacking.
    Leukemia. 2023;37:1147-1150.

  212. MORENO BERGGREN D, Garelius H, Willner Hjelm P, Nilsson L, et al
    Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.
    Leukemia. 2023;37:1103-1112.
    PubMed     Abstract available

  213. BOYIADZIS M, Zhang MJ, Chen K, Abdel-Azim H, et al
    Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.
    Leukemia. 2023;37:1006-1017.
    PubMed     Abstract available

    April 2023
  214. ANAGNOSTOU T, Yang ZZ, Jalali S, Kim HJ, et al
    Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma.
    Leukemia. 2023 Apr 28. doi: 10.1038/s41375-023-01911.
    PubMed     Abstract available

  215. KULP M, Larghero P, Alten J, Cario G, et al
    The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome.
    Leukemia. 2023 Apr 26:1-18. doi: 10.1038/s41375-023-01895.
    PubMed     Abstract available

  216. TENG JY, Yang DP, Tang C, Fang HS, et al
    Targeting DNA polymerase beta elicits synthetic lethality with mismatch repair deficiency in acute lymphoblastic leukemia.
    Leukemia. 2023 Apr 24. doi: 10.1038/s41375-023-01902.
    PubMed     Abstract available

  217. DUPLOYEZ N, Vasseur L, Kim R, Largeaud L, et al
    UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia.
    Leukemia. 2023 Apr 21. doi: 10.1038/s41375-023-01906.
    PubMed     Abstract available

  218. JIA Y, Zhang W, Basyal M, Chang KH, et al
    FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
    Leukemia. 2023 Apr 21. doi: 10.1038/s41375-023-01897.

  219. YOSHIMURA S, Panetta JC, Hu J, Li L, et al
    Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
    Leukemia. 2023 Apr 19. doi: 10.1038/s41375-023-01900.
    PubMed     Abstract available

  220. REA D, Boquimpani C, Mauro MJ, Minami Y, et al
    Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
    Leukemia. 2023 Apr 14. doi: 10.1038/s41375-023-01888.
    PubMed     Abstract available

  221. RAUSCH C, Rothenberg-Thurley M, Dufour A, Schneider S, et al
    Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
    Leukemia. 2023 Apr 11. doi: 10.1038/s41375-023-01884.
    PubMed     Abstract available

  222. DAHLEN T, Flygt H, Lubking A, Olsson-Stromberg U, et al
    The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study.
    Leukemia. 2023 Apr 10:1-4. doi: 10.1038/s41375-023-01893.

  223. LEE KH, Yoon SR, Gong JR, Choi EJ, et al
    The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial.
    Leukemia. 2023;37:807-819.
    PubMed     Abstract available

  224. HEMMINKI K, Hemminki J, Forsti A, Sud A, et al
    Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment.
    Leukemia. 2023;37:854-863.
    PubMed     Abstract available

  225. ISSA H, Swart LE, Rasouli M, Ashtiani M, et al
    Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia.
    Leukemia. 2023;37:820-834.
    PubMed     Abstract available

  226. ISSA N, Bjeije H, Wilson ER, Krishnan A, et al
    KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress.
    Leukemia. 2023;37:728-740.
    PubMed     Abstract available

  227. AKHADE VS, Liu T, Docking TR, Jiang J, et al
    Control of focal adhesion kinase activation by RUNX1-regulated miRNAs in high-risk AML.
    Leukemia. 2023;37:776-787.
    PubMed     Abstract available

  228. STAEHLE AM, Peeken JC, Vladimirov G, Hoeness ME, et al
    The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2(V617F) mutated cells.
    Leukemia. 2023;37:919-923.
    PubMed     Abstract available

    March 2023
  229. CARRATT SA, Kong GL, Coblentz C, Schonrock Z, et al
    RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development.
    Leukemia. 2023 Mar 9. doi: 10.1038/s41375-023-01862.

  230. KIYOKI Y, Kato T, Kito S, Matsuzaka T, et al
    The fatty acid elongase Elovl6 is crucial for hematopoietic stem cell engraftment and leukemia propagation.
    Leukemia. 2023 Mar 8. doi: 10.1038/s41375-023-01842.

  231. SINCLAIR PB, Cranston RE, Raninga P, Cheng J, et al
    Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia.
    Leukemia. 2023;37:636-649.
    PubMed     Abstract available

  232. RYAN SL, Peden JF, Kingsbury Z, Schwab CJ, et al
    Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia.
    Leukemia. 2023;37:518-528.
    PubMed     Abstract available

  233. TREMPENAU ML, Schuster MB, Pundhir S, Pereira MA, et al
    The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes.
    Leukemia. 2023;37:593-605.
    PubMed     Abstract available

  234. SCHWAB C, Cranston RE, Ryan SL, Butler E, et al
    Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial.
    Leukemia. 2023;37:529-538.
    PubMed     Abstract available

    February 2023
  235. MROZEK K, Kohlschmidt J, Blachly JS, Nicolet D, et al
    Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
    Leukemia. 2023 Feb 23. doi: 10.1038/s41375-023-01846.
    PubMed     Abstract available

  236. GOSSAI N, Bhojwani D, Schafer ES, Chang BH, et al
    Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.
    Leukemia. 2023 Feb 22. doi: 10.1038/s41375-023-01856.

  237. BOMBEN R, Rossi FM, Vit F, Bittolo T, et al
    Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
    Leukemia. 2023 Feb 18. doi: 10.1038/s41375-023-01845.

  238. BADAR T, Atallah E, Shallis R, Saliba AN, et al
    Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Leukemia. 2023 Feb 18. doi: 10.1038/s41375-023-01847.
    PubMed     Abstract available

  239. ARZA-APALATEGI S, Heuts BMH, Dooijes MTM, Gilissen D, et al
    High expression of an intragenic long noncoding RNA misinterpreted as high FTO oncogene expression in NPM1 mutant acute myeloid leukemia.
    Leukemia. 2023 Feb 18. doi: 10.1038/s41375-023-01844.

  240. LARRUE C, Mouche S, Lin S, Simonetta F, et al
    Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.
    Leukemia. 2023 Feb 4. doi: 10.1038/s41375-023-01835.
    PubMed     Abstract available

  241. STRAUBE J, Eifert T, Vu T, Janardhanan Y, et al
    Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.
    Leukemia. 2023 Feb 4. doi: 10.1038/s41375-023-01832.
    PubMed     Abstract available

  242. WALTI CS, Halpern AB, Xie H, Kiem ES, et al
    Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
    Leukemia. 2023;37:298-307.
    PubMed     Abstract available

  243. HE X, Xu Y, Huang D, Yu Z, et al
    P2X1 enhances leukemogenesis through PBX3-BCAT1 pathways.
    Leukemia. 2023;37:265-275.
    PubMed     Abstract available

  244. MARCELLINO BK, Yang X, Umit Kaniskan H, Brady C, et al
    An MDM2 degrader for treatment of acute leukemias.
    Leukemia. 2023;37:370-378.
    PubMed     Abstract available

    January 2023
  245. BOILA LD, Ghosh S, Bandyopadhyay SK, Jin L, et al
    KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition.
    Leukemia. 2023 Jan 31. doi: 10.1038/s41375-023-01833.
    PubMed     Abstract available

  246. HOCHHAUS A, Rea D, Boquimpani C, Minami Y, et al
    Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
    Leukemia. 2023 Jan 30. doi: 10.1038/s41375-023-01829.
    PubMed     Abstract available

  247. RYAN CE, Brander DM, Barr PM, Tyekucheva S, et al
    A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Leukemia. 2023 Jan 30. doi: 10.1038/s41375-023-01830.
    PubMed     Abstract available

  248. MORENO RUEDA LY, Bryant D, Tapper WJ, Weston-Bell NJ, et al
    The genomic landscape and clonal evolutionary trajectory of classical hairy cell leukemia.
    Leukemia. 2023 Jan 28. doi: 10.1038/s41375-023-01823.

  249. SEMBILL S, Ampatzidou M, Chaudhury S, Dworzak M, et al
    Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations.
    Leukemia. 2023 Jan 27. doi: 10.1038/s41375-023-01822.
    PubMed     Abstract available

  250. ROMINE KA, MacPherson K, Cho HJ, Kosaka Y, et al
    BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8(+) T cells.
    Leukemia. 2023 Jan 21. doi: 10.1038/s41375-023-01808.
    PubMed     Abstract available

  251. ELGHETANY MT, Cave H, De Vito R, Patnaik MM, et al
    Juvenile myelomonocytic leukemia; moving forward.
    Leukemia. 2023 Jan 20. doi: 10.1038/s41375-023-01818.

  252. MARTENS AWJ, Kavazovic I, Krapic M, Pack SM, et al
    Chronic lymphocytic leukemia presence impairs antigen-specific CD8(+) T-cell responses through epigenetic reprogramming towards short-lived effectors.
    Leukemia. 2023 Jan 19. doi: 10.1038/s41375-023-01817.
    PubMed     Abstract available

  253. MANSOURI L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, et al
    Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
    Leukemia. 2023 Jan 12. doi: 10.1038/s41375-023-01813.

  254. PETTIROSSI V, Venanzi A, Spanhol-Rosseto A, Schiavoni G, et al
    The gene mutation landscape of acute myeloid leukemia cell lines and its exemplar use to study the BCOR tumor suppressor.
    Leukemia. 2023 Jan 12. doi: 10.1038/s41375-022-01788.

  255. FORD AM, Colman S, Greaves M
    Covert pre-leukaemic clones in healthy co-twins of patients with childhood acute lymphoblastic leukaemia.
    Leukemia. 2023;37:47-52.

  256. LIESKE A, Agyeman-Duah E, Selich A, Dorpmund N, et al
    A pro B cell population forms the apex of the leukemic hierarchy in Hoxa9/Meis1-dependent AML.
    Leukemia. 2023;37:79-90.
    PubMed     Abstract available

  257. LEHRNBECHER T, Groll AH, Cesaro S, Alten J, et al
    Invasive fungal diseases impact on outcome of childhood ALL - an analysis of the international trial AIEOP-BFM ALL 2009.
    Leukemia. 2023;37:72-78.
    PubMed     Abstract available

  258. LOCATELLI F, Zugmaier G, Rizzari C, Morris JD, et al
    Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL.
    Leukemia. 2023;37:222-225.

  259. VANGALA DB, Nilius-Eliliwi V, Gerding WM, Schroers R, et al
    Optical Genome Mapping in MDS and AML as tool for structural variant profiling-comment and data update on Yang et al.: "High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of
    Leukemia. 2023;37:248-249.

  260. FENG J, Wang Y, Li B, Yu X, et al
    Loss of bisecting GlcNAcylation on MCAM of bone marrow stoma determined pro-tumoral niche in MDS/AML.
    Leukemia. 2023;37:113-121.
    PubMed     Abstract available

  261. OHKI K, Butler ER, Kiyokawa N, Hirabayashi S, et al
    Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group.
    Leukemia. 2023;37:212-216.

    December 2022
  262. AID Z, Robert E, Lopez CK, Bourgoin M, et al
    High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia.
    Leukemia. 2022 Dec 30. doi: 10.1038/s41375-022-01800.
    PubMed     Abstract available

  263. STRATMANN S, Vesterlund M, Umer HM, Eshtad S, et al
    Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children.
    Leukemia. 2022 Dec 26. doi: 10.1038/s41375-022-01796.
    PubMed     Abstract available

  264. RASTOGI N, Gonzalez JBM, Srivastava VK, Alanazi B, et al
    Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia.
    Leukemia. 2022 Dec 26. doi: 10.1038/s41375-022-01801.
    PubMed     Abstract available

  265. MANSOURI L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, et al
    Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
    Leukemia. 2022 Dec 24. doi: 10.1038/s41375-022-01802.
    PubMed     Abstract available

  266. ANDERSON NR, Sheth V, Li H, Harris MW, et al
    Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling.
    Leukemia. 2022 Dec 22. doi: 10.1038/s41375-022-01798.
    PubMed     Abstract available

  267. LI K, Du Y, Cai Y, Liu W, et al
    Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia.
    Leukemia. 2022 Dec 21. doi: 10.1038/s41375-022-01789.
    PubMed     Abstract available

  268. MILOJKOVIC D, Reynolds CJ, Sandoval DM, Pieper FP, et al
    COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Leukemia. 2022 Dec 17:1-4. doi: 10.1038/s41375-022-01787.

  269. MULLER J, Walter W, Haferlach C, Muller H, et al
    Correction: How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing.
    Leukemia. 2022 Dec 16. doi: 10.1038/s41375-022-01790.

  270. JIANG K, Li X, Wang C, Hu X, et al
    Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia.
    Leukemia. 2022 Dec 16. doi: 10.1038/s41375-022-01795.
    PubMed     Abstract available

  271. MASSACCI G, Venafra V, Latini S, Bica V, et al
    A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients.
    Leukemia. 2022 Dec 12. doi: 10.1038/s41375-022-01785.
    PubMed     Abstract available

  272. BORKHARDT A, Schuz J, Trubenbach C, Wellbrock M, et al
    Temporal changes of the incidence of childhood B-cell precursor acute lymphoblastic leukaemia in Germany during the COVID-19 pandemic.
    Leukemia. 2022;36:2908-2911.

  273. HUBER S, Haferlach T, Meggendorfer M, Hutter S, et al
    SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase.
    Leukemia. 2022;36:2927-2930.

  274. ZEIDAN AM, Bewersdorf JP, Buckstein R, Sekeres MA, et al
    Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
    Leukemia. 2022;36:2939-2946.

  275. HUBER S, Haferlach T, Meggendorfer M, Hutter S, et al
    SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.
    Leukemia. 2022;36:2894-2902.
    PubMed     Abstract available

  276. BENYOUCEF A, Haigh K, Cuddihy A, Haigh JJ, et al
    JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.
    Leukemia. 2022;36:2802-2816.
    PubMed     Abstract available

  277. ZHANG Y, Wu J, Qin T, Xu Z, et al
    Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.
    Leukemia. 2022;36:2875-2882.
    PubMed     Abstract available

    November 2022
  278. MOLICA S, Giannarelli D
    Retraction Note: Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis.
    Leukemia. 2022 Nov 30. doi: 10.1038/s41375-022-01771.

  279. ZEIDAN AM, Bewersdorf JP, Hasle V, Shallis RM, et al
    Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.
    Leukemia. 2022 Nov 27. doi: 10.1038/s41375-022-01766.

  280. HU H, Saha N, Yang Y, Ahmad E, et al
    The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t(11;19) Leukemia.
    Leukemia. 2022 Nov 26. doi: 10.1038/s41375-022-01765.
    PubMed     Abstract available

  281. PARAS G, Othus M, Schonhoff K, Shaw C, et al
    Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms.
    Leukemia. 2022 Nov 25. doi: 10.1038/s41375-022-01745.

  282. STEINHAUSER S, Silva P, Lenk L, Beder T, et al
    Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).
    Leukemia. 2022 Nov 21. doi: 10.1038/s41375-022-01751.
    PubMed     Abstract available

  283. LING VY, Straube J, Godfrey W, Haldar R, et al
    Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
    Leukemia. 2022 Nov 18. doi: 10.1038/s41375-022-01755.
    PubMed     Abstract available

  284. CALVO X
    Should we give oligomonocytic chronic myelomonocytic leukemia a higher prominence in the next WHO Classification of Haematolymphoid Tumors?
    Leukemia. 2022 Nov 16. pii: 10.1038/s41375-022-01760.

  285. CHEUNG LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, et al
    Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
    Leukemia. 2022 Nov 15. pii: 10.1038/s41375-022-01746.
    PubMed     Abstract available

  286. DUMAS PY, Raffoux E, Berard E, Bertoli S, et al
    Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
    Leukemia. 2022 Nov 14. pii: 10.1038/s41375-022-01742.
    PubMed     Abstract available

  287. SHER S, Whipp E, Walker J, Zhang P, et al
    VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
    Leukemia. 2022 Nov 14. pii: 10.1038/s41375-022-01758.
    PubMed     Abstract available

  288. MANDELL JD, Fisk JN, Cyrenne E, Xu ML, et al
    Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia.
    Leukemia. 2022 Nov 11. pii: 10.1038/s41375-022-01752.

  289. JIMBO K, Hattori A, Koide S, Ito T, et al
    Genetic deletion and pharmacologic inhibition of E3 ubiquitin ligase HOIP impairs the propagation of myeloid leukemia.
    Leukemia. 2022 Nov 9. pii: 10.1038/s41375-022-01750.
    PubMed     Abstract available

  290. KOSCHADE SE, Klann K, Shaid S, Vick B, et al
    Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
    Leukemia. 2022 Nov 8. pii: 10.1038/s41375-022-01721.

  291. MULLER J, Walter W, Haferlach C, Muller H, et al
    How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing.
    Leukemia. 2022 Nov 5. pii: 10.1038/s41375-022-01743.

  292. ADAMO A, Chin P, Keane P, Assi SA, et al
    Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia.
    Leukemia. 2022 Nov 4. pii: 10.1038/s41375-022-01744.
    PubMed     Abstract available

  293. LI M, Ye J, Xia Y, Li M, et al
    METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4.
    Leukemia. 2022;36:2586-2595.
    PubMed     Abstract available

  294. BUHRER ED, Amrein MA, Forster S, Isringhausen S, et al
    Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.
    Leukemia. 2022;36:2634-2646.
    PubMed     Abstract available

  295. FISKUS W, Daver N, Boettcher S, Mill CP, et al
    Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
    Leukemia. 2022;36:2729-2733.

  296. BOUTZEN H, Madani Tonekaboni SA, Chan-Seng-Yue M, Murison A, et al
    A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome.
    Leukemia. 2022;36:2690-2704.
    PubMed     Abstract available

  297. MEKINIAN A, Zhao LP, Chevret S, Desseaux K, et al
    A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
    Leukemia. 2022;36:2739-2742.

  298. YANG S, Kay NE, Shi M, Hanson CA, et al
    Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?
    Leukemia. 2022;36:2743-2747.

    October 2022
  299. CEOLIN V, Brivio E, van Tinteren H, Rheingold SR, et al
    Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia.
    Leukemia. 2022 Oct 30. pii: 10.1038/s41375-022-01740.
    PubMed     Abstract available

  300. ZHOU X, Zhang P, Aryal S, Zhang L, et al
    UTX loss alters therapeutic responses in KMT2A-rearranged acute myeloid leukemia.
    Leukemia. 2022 Oct 29. pii: 10.1038/s41375-022-01741.

  301. SENAPATI J, Jabbour E, Kantarjian H, Short NJ, et al
    Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia.
    Leukemia. 2022 Oct 29. pii: 10.1038/s41375-022-01736.
    PubMed     Abstract available

  302. COUSINS A, Olivares O, Markert E, Manoharan A, et al
    Central nervous system involvement in childhood acute lymphoblastic leukemia is linked to upregulation of cholesterol biosynthetic pathways.
    Leukemia. 2022 Oct 26. pii: 10.1038/s41375-022-01722.

  303. GARCIA-GISBERT N, Arenillas L, Roman-Bravo D, Rodriguez-Sevilla JJ, et al
    Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia.
    Leukemia. 2022 Oct 22. pii: 10.1038/s41375-022-01733.

  304. XU JJ, Chalk AM, Wall M, Langdon WY, et al
    Srsf2(P95H/+) co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice.
    Leukemia. 2022 Oct 21. pii: 10.1038/s41375-022-01727.
    PubMed     Abstract available

  305. THASTRUP M, Duguid A, Mirian C, Schmiegelow K, et al
    Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions.
    Leukemia. 2022 Oct 20. pii: 10.1038/s41375-022-01714.
    PubMed     Abstract available

  306. HAAS OA, Borkhardt A
    Hyperdiploidy: the longest known, most prevalent, and most enigmatic form of acute lymphoblastic leukemia in children.
    Leukemia. 2022 Oct 20. pii: 10.1038/s41375-022-01720.
    PubMed     Abstract available

  307. SHORT NJ, Fu C, Berry DA, Walter RB, et al
    Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis.
    Leukemia. 2022 Oct 19. pii: 10.1038/s41375-022-01692.
    PubMed     Abstract available

  308. QIU S, Kumar H, Yan C, Li H, et al
    Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition.
    Leukemia. 2022 Oct 11. pii: 10.1038/s41375-022-01719.
    PubMed     Abstract available

  309. CARRATT SA, Braun TP, Coblentz C, Schonrock Z, et al
    Correction to: Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Leukemia. 2022 Oct 4. pii: 10.1038/s41375-022-01710.

  310. ALLERT C, Waclawiczek A, Zimmermann SMN, Gollner S, et al
    Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML.
    Leukemia. 2022;36:2418-2429.
    PubMed     Abstract available

  311. LEE AC, Pingali SR, Pinilla-Ibarz JA, Atchison ML, et al
    Loss of AID exacerbates the malignant progression of CLL.
    Leukemia. 2022;36:2430-2442.
    PubMed     Abstract available

  312. RANIERI R, Pianigiani G, Sciabolacci S, Perriello VM, et al
    Current status and future perspectives in targeted therapy of NPM1-mutated AML.
    Leukemia. 2022;36:2351-2367.
    PubMed     Abstract available

  313. BURNS SS, Kumar R, Pasupuleti SK, So K, et al
    Il-1r1 drives leukemogenesis induced by Tet2 loss.
    Leukemia. 2022;36:2531-2534.

  314. ZHANG TJ, Xu ZJ, Wen XM, Gu Y, et al
    SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm.
    Leukemia. 2022;36:2488-2498.
    PubMed     Abstract available

    September 2022
  315. ZHANG H, Bu C, Peng Z, Li G, et al
    Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis.
    Leukemia. 2022 Sep 23. pii: 10.1038/s41375-022-01703.
    PubMed     Abstract available

  316. SEMENZATO G, Teramo A, Calabretto G, Gasparini VR, et al
    All that glitters is not LGL Leukemia.
    Leukemia. 2022 Sep 15. pii: 10.1038/s41375-022-01695.
    PubMed     Abstract available

  317. THOMPSON PA, Jiang X, Banerjee P, Basar R, et al
    A phase two study of high dose blinatumomab in Richter's syndrome.
    Leukemia. 2022;36:2228-2232.
    PubMed     Abstract available

  318. CUTHILL KM, Zhang Y, Pepper A, Boelen L, et al
    Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL.
    Leukemia. 2022;36:2233-2241.
    PubMed     Abstract available

    August 2022
  319. BERGERON BP, Diedrich JD, Zhang Y, Barnett KR, et al
    Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia.
    Leukemia. 2022 Aug 26. pii: 10.1038/s41375-022-01685.
    PubMed     Abstract available

  320. KOSCHADE SE, Klann K, Shaid S, Vick B, et al
    Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
    Leukemia. 2022 Aug 23. pii: 10.1038/s41375-022-01678.
    PubMed     Abstract available

  321. YEN R, Grasedieck S, Wu A, Lin H, et al
    Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial.
    Leukemia. 2022 Aug 23. pii: 10.1038/s41375-022-01680.
    PubMed     Abstract available

  322. HEHLMANN R, Lauseker M, Voskanyan A, Fabarius A, et al
    Impact of emerging ACA on survival in chronic myeloid leukemia (CML).
    Leukemia. 2022 Aug 23. pii: 10.1038/s41375-022-01681.

  323. ARNIANI S, Pierini V, Pellanera F, Matteucci C, et al
    Chromothripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adults.
    Leukemia. 2022 Aug 16. pii: 10.1038/s41375-022-01671.
    PubMed     Abstract available

  324. DESPREZ C, Riou J, Peterlin P, Marchand T, et al
    Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia-a Grand Ouest Against Leukemia (GOAL) study.
    Leukemia. 2022 Aug 12. pii: 10.1038/s41375-022-01677.
    PubMed     Abstract available

  325. KONG W, He L, Zhu J, Bruck O, et al
    An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia.
    Leukemia. 2022 Aug 9. pii: 10.1038/s41375-022-01662.
    PubMed     Abstract available

  326. ZUNA J, Hovorkova L, Krotka J, Koehrmann A, et al
    Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
    Leukemia. 2022 Aug 6. pii: 10.1038/s41375-022-01668.
    PubMed     Abstract available

  327. MOSTOFI N, Shaw C, Walter RB, Percival MM, et al
    Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patients.
    Leukemia. 2022 Aug 5. pii: 10.1038/s41375-022-01664.

  328. JAHN N, Jahn E, Saadati M, Bullinger L, et al
    Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
    Leukemia. 2022 Aug 3. pii: 10.1038/s41375-022-01650.
    PubMed     Abstract available

  329. FENG P, Chen D, Wang X, Li Y, et al
    Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia.
    Leukemia. 2022 Aug 1. pii: 10.1038/s41375-022-01651.
    PubMed     Abstract available

  330. MEYER AE, Stelloh C, Pulakanti K, Burns R, et al
    Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.
    Leukemia. 2022;36:2032-2041.
    PubMed     Abstract available

  331. KONGKIATKAMON S, Terkawi L, Guan Y, Adema V, et al
    Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms.
    Leukemia. 2022;36:2086-2096.
    PubMed     Abstract available

  332. GBADAMOSI MO, Shastri VM, Elsayed AH, Ries R, et al
    A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
    Leukemia. 2022;36:2022-2031.
    PubMed     Abstract available

  333. XIANG P, Yang X, Escano L, Dhillon I, et al
    Elucidating the importance and regulation of key enhancers for human MEIS1 expression.
    Leukemia. 2022;36:1980-1989.
    PubMed     Abstract available

    July 2022
  334. SOVERINI S, De Santis S, Martelli M, Monaldi C, et al
    Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
    Leukemia. 2022 Jul 30. pii: 10.1038/s41375-022-01660.
    PubMed     Abstract available

  335. ONG JZL, Yokomori R, Wong RWJ, Tan TK, et al
    Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.
    Leukemia. 2022 Jul 30. pii: 10.1038/s41375-022-01655.
    PubMed     Abstract available

  336. ESCUDERO A, Takagi M, Auer F, Friedrich UA, et al
    Clinical and immunophenotypic characteristics of familial leukemia predisposition caused by PAX5 germline variants.
    Leukemia. 2022 Jul 28. pii: 10.1038/s41375-022-01661.

  337. SCHONFELD L, Rinke J, Hinze A, Nagel SN, et al
    ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
    Leukemia. 2022 Jul 28. pii: 10.1038/s41375-022-01648.
    PubMed     Abstract available

  338. GROARKE EM, Patel BA, Shalhoub R, Gutierrez-Rodrigues F, et al
    Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia.
    Leukemia. 2022 Jul 27. pii: 10.1038/s41375-022-01636.
    PubMed     Abstract available

  339. JANSSEN JJWM, Lowenberg B, Manz M, Biemond BJ, et al
    Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
    Leukemia. 2022 Jul 22. pii: 10.1038/s41375-022-01657.
    PubMed     Abstract available

  340. ROHNERT MA, Kramer M, Schadt J, Ensel P, et al
    Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.
    Leukemia. 2022 Jul 18. pii: 10.1038/s41375-022-01647.
    PubMed     Abstract available

  341. SIGMUND AM, Huang Y, Ruppert AS, Maddocks K, et al
    Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib.
    Leukemia. 2022 Jul 16. pii: 10.1038/s41375-022-01640.

  342. LIU L, Patnana PK, Xie X, Frank D, et al
    GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia.
    Leukemia. 2022 Jul 8. pii: 10.1038/s41375-022-01635.
    PubMed     Abstract available

  343. CARRATT SA, Braun TP, Coblentz C, Schonrock Z, et al
    Correction: Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Leukemia. 2022 Jul 6. pii: 10.1038/s41375-022-01646.

  344. MOKER P, Zur Stadt U, Zimmermann M, Alawi M, et al
    Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia.
    Leukemia. 2022 Jul 5. pii: 10.1038/s41375-022-01626.

  345. FUHRMANN I, Lenk M, Haferlach T, Stengel A, et al
    AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics.
    Leukemia. 2022;36:1939-1942.

  346. SALMON M, White HE, Zizkova H, Gottschalk A, et al
    Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
    Leukemia. 2022;36:1879-1886.
    PubMed     Abstract available

  347. WHITE HE, Salmon M, Albano F, Andersen CSA, et al
    Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.
    Leukemia. 2022;36:1834-1842.
    PubMed     Abstract available

  348. RICHTER-PECHANSKA P, Kunz JB, Rausch T, Erarslan-Uysal B, et al
    Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution.
    Leukemia. 2022;36:1759-1768.
    PubMed     Abstract available

  349. CHEN L, Zheng Y, Yu K, Chen S, et al
    Changing causes of death in persons with haematological cancers 1975-2016.
    Leukemia. 2022;36:1850-1860.
    PubMed     Abstract available

  350. MAMIDI MK, Mahmud H, Maiti GP, Mendez MT, et al
    Idelalisib activates AKT via increased recruitment of PI3Kdelta/PI3Kbeta to BCR signalosome while reducing PDK1 in post-therapy CLL cells.
    Leukemia. 2022;36:1806-1817.
    PubMed     Abstract available

  351. PIANIGIANI G, Rocchio F, Peruzzi S, Andresen V, et al
    The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein.
    Leukemia. 2022;36:1931-1934.

  352. YANG S, Zhang XS, Gale RP, Huang XJ, et al
    Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase.
    Leukemia. 2022;36:1818-1824.
    PubMed     Abstract available

  353. SOFI MH, Tian L, Schutt S, Khan I, et al
    Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway.
    Leukemia. 2022;36:1907-1915.
    PubMed     Abstract available

  354. KAISRLIKOVA M, Vesela J, Kundrat D, Votavova H, et al
    RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.
    Leukemia. 2022;36:1898-1906.
    PubMed     Abstract available

  355. MENEZES AC, Jones R, Shrestha A, Nicholson R, et al
    Increased expression of RUNX3 inhibits normal human myeloid development.
    Leukemia. 2022;36:1769-1780.
    PubMed     Abstract available

    June 2022
  356. VON TRESCKOW J, Cramer P, Robrecht S, Langerbeins P, et al
    Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.
    Leukemia. 2022 Jun 25. pii: 10.1038/s41375-022-01629.

  357. WEI Y, Kanagal-Shamanna R, Zheng H, Bao N, et al
    Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
    Leukemia. 2022 Jun 14. pii: 10.1038/s41375-022-01605.
    PubMed     Abstract available

  358. BUENO-COSTA A, Pineyro D, Garcia-Prieto CA, Ortiz-Barahona V, et al
    Remodeling of the m(6)A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages.
    Leukemia. 2022 Jun 9. pii: 10.1038/s41375-022-01621.

  359. PANINA SB, Pei J, Baran N, Tjahjono E, et al
    Novel mitochondria-targeting compounds selectively kill human leukemia cells.
    Leukemia. 2022 Jun 7. pii: 10.1038/s41375-022-01614.
    PubMed     Abstract available

  360. ZARNEGAR-LUMLEY S, Caldwell KJ, Rubnitz JE
    Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies.
    Leukemia. 2022 Jun 6. pii: 10.1038/s41375-022-01619.
    PubMed     Abstract available

  361. ORVAIN C, Othus M, Johal G, Hunault-Berger M, et al
    Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia.
    Leukemia. 2022 Jun 3. pii: 10.1038/s41375-022-01624.
    PubMed     Abstract available

  362. TOKSVANG LN, Lee SHR, Yang JJ, Schmiegelow K, et al
    Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
    Leukemia. 2022 Jun 2. pii: 10.1038/s41375-022-01591.
    PubMed     Abstract available

  363. ZHANG XS, Gale RP, Li ZY, Zhang MY, et al
    Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy.
    Leukemia. 2022 Jun 1. pii: 10.1038/s41375-022-01616.
    PubMed     Abstract available

  364. MANLEY PW
    Evidence supporting that the attribution of first success in use of arsenic for the treatment of leukaemia should be to David Lissauer (1836-1892).
    Leukemia. 2022;36:1697-1698.

  365. CESARO S, Ljungman P, Mikulska M, Hirsch HH, et al
    Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9).
    Leukemia. 2022;36:1467-1480.
    PubMed     Abstract available

  366. LASZLO GS, Orozco JJ, Kehret AR, Lunn MC, et al
    Development of [(211)At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies.
    Leukemia. 2022;36:1485-1491.
    PubMed     Abstract available

  367. TRAVAGLINI S, Ottone T, Angelini DF, Fiori V, et al
    CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITD(mut) AML.
    Leukemia. 2022;36:1685-1688.

    May 2022
  368. BRUMMENDORF TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, et al
    Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
    Leukemia. 2022 May 28. pii: 10.1038/s41375-022-01589.
    PubMed     Abstract available

  369. MOSHIRI H, Cabrera Riofrio DA, Lim YJ, Lauhasurayotin S, et al
    Germline PTPN13 mutations in patients with bone marrow failure and acute lymphoblastic leukemia.
    Leukemia. 2022 May 28. pii: 10.1038/s41375-022-01610.

  370. MAN CH, Zeng X, Lam W, Ng TCC, et al
    Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication.
    Leukemia. 2022 May 27. pii: 10.1038/s41375-022-01606.
    PubMed     Abstract available

  371. VINADO AC, Calvo IA, Cenzano I, Olaverri D, et al
    The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.
    Leukemia. 2022 May 26. pii: 10.1038/s41375-022-01601.
    PubMed     Abstract available

  372. AGATHANGELIDIS A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, et al
    Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL.
    Leukemia. 2022 May 25. pii: 10.1038/s41375-022-01604.
    PubMed     Abstract available

  373. GRIMM J, Bhayadia R, Gack L, Heckl D, et al
    Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core.
    Leukemia. 2022 May 24. pii: 10.1038/s41375-022-01603.

  374. JAKEL H, Taschler M, Jung K, Weinl C, et al
    Inability to phosphorylate Y88 of p27(Kip1) enforces reduced p27 protein levels and accelerates leukemia progression.
    Leukemia. 2022 May 21. pii: 10.1038/s41375-022-01598.
    PubMed     Abstract available

  375. CURTISS BM, VanCampen J, Macaraeg J, Kong GL, et al
    PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.
    Leukemia. 2022 May 19. pii: 10.1038/s41375-022-01594.
    PubMed     Abstract available

  376. HENGEVELD PJ, Ertem YE, Dubois JMN, Mellink CHM, et al
    Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21(R110).
    Leukemia. 2022 May 18. pii: 10.1038/s41375-022-01600.

  377. OLIVEIRA ML, Veloso A, Garcia EG, Iyer S, et al
    Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia.
    Leukemia. 2022 May 17. pii: 10.1038/s41375-022-01590.
    PubMed     Abstract available

  378. RUSYN L, Reinartz S, Nikiforov A, Mikhael N, et al
    The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia.
    Leukemia. 2022 May 6. pii: 10.1038/s41375-022-01586.
    PubMed     Abstract available

  379. BACCARANI M, Bonifazi F, Soverini S, Castagnetti F, et al
    Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.
    Leukemia. 2022;36:1227-1236.
    PubMed     Abstract available

  380. KHANLARI M, Yin CC, Takahashi K, Lachowiez C, et al
    Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.
    Leukemia. 2022;36:1343-1350.
    PubMed     Abstract available

  381. GBYLI R, Song Y, Liu W, Gao Y, et al
    In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
    Leukemia. 2022;36:1313-1323.
    PubMed     Abstract available

  382. CAPLAN M, Wittorf KJ, Weber KK, Swenson SA, et al
    Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML.
    Leukemia. 2022;36:1296-1305.
    PubMed     Abstract available

  383. BODDICKER NJ, Achenbach SJ, Parikh SA, Kleinstern G, et al
    Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis.
    Leukemia. 2022;36:1404-1407.

  384. NACHMIAS B, Khan DH, Voisin V, Mer AS, et al
    IPO11 regulates the nuclear import of BZW1/2 and is necessary for AML cells and stem cells.
    Leukemia. 2022;36:1283-1295.
    PubMed     Abstract available

    April 2022
  385. PARDIEU B, Pasanisi J, Ling F, Dal Bello R, et al
    Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia.
    Leukemia. 2022 Apr 26. pii: 10.1038/s41375-022-01573.
    PubMed     Abstract available

  386. JACOBY E, Ghorashian S, Vormoor B, De Moerloose B, et al
    CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study.
    Leukemia. 2022 Apr 25. pii: 10.1038/s41375-022-01546.
    PubMed     Abstract available

  387. PENNESI E, Michels N, Brivio E, van der Velden VHJ, et al
    Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
    Leukemia. 2022 Apr 25. pii: 10.1038/s41375-022-01576.
    PubMed     Abstract available

  388. STRANAHAN AW, Berezniuk I, Chakraborty S, Feller F, et al
    Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.
    Leukemia. 2022 Apr 23. pii: 10.1038/s41375-022-01579.
    PubMed     Abstract available

  389. MASCHMEYER G, Bullinger L, Garcia-Vidal C, Herbrecht R, et al
    Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplanta
    Leukemia. 2022 Apr 19. pii: 10.1038/s41375-022-01570.

  390. ZARLING LC, Othus M, Sandmaier BM, Milano F, et al
    Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
    Leukemia. 2022 Apr 19. pii: 10.1038/s41375-022-01574.
    PubMed     Abstract available

  391. LAETSCH TW, Maude SL, Balduzzi A, Rives S, et al
    Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2022 Apr 14. pii: 10.1038/s41375-022-01550.
    PubMed     Abstract available

  392. JIMBO K, Nakajima-Takagi Y, Ito T, Koide S, et al
    Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of beta-catenin degradation.
    Leukemia. 2022 Apr 13. pii: 10.1038/s41375-022-01564.
    PubMed     Abstract available

  393. GHIA EM, Rassenti LZ, Choi MY, Quijada-Alamo M, et al
    High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
    Leukemia. 2022 Apr 13. pii: 10.1038/s41375-022-01543.
    PubMed     Abstract available

  394. SASAKI Y, Kantarjian HM, Short NJ, Wang F, et al
    Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
    Leukemia. 2022 Apr 11. pii: 10.1038/s41375-022-01568.

  395. BODAAR K, Yamagata N, Barthe A, Landrigan J, et al
    JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.
    Leukemia. 2022 Apr 11. pii: 10.1038/s41375-022-01558.
    PubMed     Abstract available

  396. CHEN R, Chen Y, Xiong P, Zheleva D, et al
    Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.
    Leukemia. 2022 Apr 5. pii: 10.1038/s41375-022-01553.
    PubMed     Abstract available

  397. CLESHAM K, Walf-Vorderwulbecke V, Gasparoli L, Virely C, et al
    Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.
    Leukemia. 2022 Apr 2. pii: 10.1038/s41375-022-01554.
    PubMed     Abstract available

  398. MASCHMEYER G, Bullinger L, Garcia-Vidal C, Herbrecht R, et al
    Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT),
    Leukemia. 2022 Apr 2. pii: 10.1038/s41375-022-01556.
    PubMed     Abstract available

  399. GUNNARSSON R, Yang M, Biloglav A, Lazarevic V, et al
    Single base substitution and insertion/deletion mutational signatures in adult core binding factor acute myeloid leukemia.
    Leukemia. 2022 Apr 1. pii: 10.1038/s41375-022-01552.

  400. BLUEMN T, Schmitz J, Zheng Y, Burns R, et al
    Differential roles of BAF and PBAF subunits, Arid1b and Arid2, in MLL-AF9 leukemogenesis.
    Leukemia. 2022;36:946-955.
    PubMed     Abstract available

  401. WILSON ER, Helton NM, Heath SE, Fulton RS, et al
    Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells.
    Leukemia. 2022;36:935-945.
    PubMed     Abstract available

  402. RECHER C, Rollig C, Berard E, Bertoli S, et al
    Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
    Leukemia. 2022;36:913-922.
    PubMed     Abstract available

    March 2022
  403. DECROOCQ J, Birsen R, Montersino C, Chaskar P, et al
    RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.
    Leukemia. 2022 Mar 30. pii: 10.1038/s41375-022-01541.
    PubMed     Abstract available

  404. WALSH C, Hunter A, Lasho T, Finke C, et al
    Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia.
    Leukemia. 2022 Mar 29. pii: 10.1038/s41375-022-01551.

  405. JENSEN KS, Oskarsson T, Lahteenmaki PM, Flaegstad T, et al
    Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study.
    Leukemia. 2022 Mar 21. pii: 10.1038/s41375-022-01540.
    PubMed     Abstract available

  406. RASMUSSEN B, Gohring G, Bernard E, Nilsson L, et al
    "Randomized phase II study of azacitidine +/- lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
    Leukemia. 2022 Mar 11. pii: 10.1038/s41375-022-01537.

  407. FOURNIER E, Heiblig M, Lespinasse C, Flandrin-Gresta P, et al
    Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.
    Leukemia. 2022 Mar 7. pii: 10.1038/s41375-022-01534.

  408. MORETTI S, Abdel-Aziz AK, Ceccacci E, Pallavicini I, et al
    Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication.
    Leukemia. 2022 Mar 4. pii: 10.1038/s41375-022-01530.
    PubMed     Abstract available

  409. BALASUBRAMANIAN SK, Azmi AS, Maciejewski J
    Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms.
    Leukemia. 2022;36:601-612.
    PubMed     Abstract available

  410. CHARLET A, Kappenstein M, Keye P, Klasener K, et al
    The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML.
    Leukemia. 2022;36:701-711.
    PubMed     Abstract available

  411. STAVAST CJ, van Zuijen I, Karkoulia E, Ozcelik A, et al
    The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis.
    Leukemia. 2022;36:687-700.
    PubMed     Abstract available

  412. LI P, White T, Xie W, Cui W, et al
    AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome.
    Leukemia. 2022;36:664-674.
    PubMed     Abstract available

  413. MOORMAN AV, Barretta E, Butler ER, Ward EJ, et al
    Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.
    Leukemia. 2022;36:625-636.
    PubMed     Abstract available

  414. DUCHMANN M, Wagner-Ballon O, Boyer T, Cheok M, et al
    Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML.
    Leukemia. 2022;36:656-663.
    PubMed     Abstract available

  415. RAJAN V, Collett K, Woodside R, Prykhozhij SV, et al
    Stress hematopoiesis induces a proliferative advantage in TET2 deficiency.
    Leukemia. 2022;36:809-820.
    PubMed     Abstract available

    February 2022
  416. ZHANG XS, Gale RP, Zhang MJ, Huang XJ, et al
    A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy.
    Leukemia. 2022 Feb 22. pii: 10.1038/s41375-022-01527.
    PubMed     Abstract available

  417. PIYA S, Yang Y, Bhattacharya S, Sharma P, et al
    Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL.
    Leukemia. 2022 Feb 16. pii: 10.1038/s41375-022-01516.
    PubMed     Abstract available

  418. HALPERN AB, Othus M, Alcorn G, Ali Z, et al
    Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm.
    Leukemia. 2022 Feb 16. pii: 10.1038/s41375-022-01524.

  419. VACA AM, Ioannou N, Sivina M, Vlachonikola E, et al
    Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.
    Leukemia. 2022 Feb 11. pii: 10.1038/s41375-022-01519.
    PubMed     Abstract available

  420. SASAKI Y, Kantarjian HM, Short NJ, Wang F, et al
    Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
    Leukemia. 2022 Feb 7. pii: 10.1038/s41375-021-01496.
    PubMed     Abstract available

  421. LEE KL, Ko TK, Saw NYL, Javed A, et al
    Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia.
    Leukemia. 2022 Feb 4. pii: 10.1038/s41375-022-01508.

  422. ZHANG Z, Lu Y, Qi Y, Xu Y, et al
    CDK19 regulates the proliferation of hematopoietic stem cells and acute myeloid leukemia cells by suppressing p53-mediated transcription of p21.
    Leukemia. 2022 Feb 2. pii: 10.1038/s41375-022-01512.
    PubMed     Abstract available

  423. CHEN X, Fromm JR, Naresh KN
    "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?
    Leukemia. 2022;36:327-332.

  424. QIAO J, Liang C, Zhao D, Nguyen LXT, et al
    Spred1 deficit promotes treatment resistance and transformation of chronic phase CML.
    Leukemia. 2022;36:492-506.
    PubMed     Abstract available

  425. PERNER F, Schnoeder TM, Xiong Y, Jayavelu AK, et al
    YBX1 mediates translation of oncogenic transcripts to control cell competition in AML.
    Leukemia. 2022;36:426-437.
    PubMed     Abstract available

  426. PULIKKOTTIL AJ, Bamezai S, Ammer T, Mohr F, et al
    TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways.
    Leukemia. 2022;36:416-425.
    PubMed     Abstract available

  427. WAWRZYNIECKA PA, Ibrahim L, Gritti G, Pule MA, et al
    Chimeric antigen receptor T cells for gamma-delta T cell malignancies.
    Leukemia. 2022;36:577-579.

  428. CAPPELLI LV, Meggendorfer M, Baer C, Nadarajah N, et al
    Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration.
    Leukemia. 2022;36:394-402.
    PubMed     Abstract available

    January 2022
  429. WEN Z, Finn R, Gao X, Li L, et al
    Tcof1 haploinsufficiency promotes early T cell precursor-like leukemia in Nras(Q61R/+) mice.
    Leukemia. 2022 Jan 26. pii: 10.1038/s41375-022-01510.

  430. KOPMAR NE, Othus M, Gardner KM, Shaw C, et al
    Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies.
    Leukemia. 2022 Jan 20. pii: 10.1038/s41375-022-01509.

  431. WANG X, Dong Z, Awuah D, Chang WC, et al
    CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.
    Leukemia. 2022 Jan 18. pii: 10.1038/s41375-021-01477.
    PubMed     Abstract available

  432. KAPLAN ZLR, van Leeuwen N, Posthuma EFM, Visser O, et al
    Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something.
    Leukemia. 2022 Jan 17. pii: 10.1038/s41375-021-01503.

  433. GOODENOUGH CG, Diouf B, Yang W, Sapkota Y, et al
    Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia.
    Leukemia. 2022 Jan 4. pii: 10.1038/s41375-021-01484.

  434. SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
    Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia.
    Leukemia. 2022 Jan 1. pii: 10.1038/s41375-021-01485.

  435. DE BEAUCHAMP L, Himonas E, Helgason GV
    Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia.
    Leukemia. 2022;36:1-12.
    PubMed     Abstract available

  436. YANG J, Weisberg EL, Liu X, Magin RS, et al
    Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
    Leukemia. 2022;36:210-220.
    PubMed     Abstract available

  437. TRAN TM, Philipp J, Bassi JS, Nibber N, et al
    The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis.
    Leukemia. 2022;36:68-79.
    PubMed     Abstract available

  438. CANDELLI T, Schneider P, Garrido Castro P, Jones LA, et al
    Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics.
    Leukemia. 2022;36:58-67.
    PubMed     Abstract available

  439. TETTAMANTI S, Pievani A, Biondi A, Dotti G, et al
    Catch me if you can: how AML and its niche escape immunotherapy.
    Leukemia. 2022;36:13-22.
    PubMed     Abstract available

  440. LIM TL, Lieberman DB, Davis AR, Loren AW, et al
    Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.
    Leukemia. 2022;36:283-287.

  441. PEGLIASCO J, Hirsch P, Marzac C, Isnard F, et al
    Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
    Leukemia. 2022;36:126-137.
    PubMed     Abstract available

  442. PEPPER AGS, Zucchetto A, Norris K, Tissino E, et al
    Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
    Leukemia. 2022;36:271-274.

  443. ORAN B, Champlin RE, Wang F, Tanaka T, et al
    Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.
    Leukemia. 2022;36:257-262.
    PubMed     Abstract available

  444. BOZIC T, Kuo CC, Hapala J, Franzen J, et al
    Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns.
    Leukemia. 2022;36:80-89.
    PubMed     Abstract available

    December 2021
  445. MELLINGHOFF SC, Robrecht S, Mayer L, Weskamm LM, et al
    SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.
    Leukemia. 2021 Dec 22. pii: 10.1038/s41375-021-01500.

  446. SPOHR C, Poggio T, Andrieux G, Schonberger K, et al
    Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.
    Leukemia. 2021 Dec 13. pii: 10.1038/s41375-021-01490.
    PubMed     Abstract available

  447. ASSMANN JLJC, Leon LG, Stavast CJ, van den Bogaerdt SE, et al
    miR-181a is a novel player in the STAT3-mediated survival network of TCRalphabeta+ CD8+ T large granular lymphocyte leukemia.
    Leukemia. 2021 Dec 6. pii: 10.1038/s41375-021-01480.
    PubMed     Abstract available

  448. SUNTHANKAR KI, Jenkins MT, Cote CH, Patel SB, et al
    Isocitrate dehydrogenase mutations are associated with altered IL-1beta responses in acute myeloid leukemia.
    Leukemia. 2021 Dec 2. pii: 10.1038/s41375-021-01487.
    PubMed     Abstract available

  449. CHATZIKONSTANTINOU T, Kapetanakis A, Scarfo L, Karakatsoulis G, et al
    COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
    Leukemia. 2021;35:3444-3454.
    PubMed     Abstract available

  450. YANG S, Kay NE, Shi M, Ossenkoppele G, et al
    Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?
    Leukemia. 2021;35:3364-3370.

  451. PATEL SB, Nemkov T, Stefanoni D, Benavides GA, et al
    Metabolic alterations mediated by STAT3 promotes drug persistence in CML.
    Leukemia. 2021;35:3371-3382.
    PubMed     Abstract available

  452. STEENSMA DP, Wermke M, Klimek VM, Greenberg PL, et al
    Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
    Leukemia. 2021;35:3542-3550.
    PubMed     Abstract available

  453. GEORGIADIS C, Rasaiyaah J, Gkazi SA, Preece R, et al
    Base-edited CAR T cells for combinational therapy against T cell malignancies.
    Leukemia. 2021;35:3466-3481.
    PubMed     Abstract available

    November 2021
  454. JOHNSON DT, Zhou J, Kroll AV, Fang RH, et al
    Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy.
    Leukemia. 2021 Nov 29. pii: 10.1038/s41375-021-01432.
    PubMed     Abstract available

  455. SHIMOMURA Y, Sobue T, Hirabayashi S, Kondo T, et al
    Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia.
    Leukemia. 2021 Nov 24. pii: 10.1038/s41375-021-01474.
    PubMed     Abstract available

  456. HORAK P, Uhrig S, Witzel M, Gil-Farina I, et al
    Publisher Correction: Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia.
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01364.

  457. ROESSNER PM, Seiffert M
    Publisher Correction: T cells in chronic lymphocytic leukemia: guardians or drivers of disease?
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01362.

  458. WALTER RB, Hochhaus A, Gale RP
    Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946-October 8, 2021).
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01467.

  459. JEON S, de Smith AJ, Li S, Chen M, et al
    Genome-wide trans-ethnic meta-analysis identifies novel susceptibility loci for childhood acute lymphoblastic leukemia.
    Leukemia. 2021 Nov 8. pii: 10.1038/s41375-021-01465.

  460. SPANJAART AM, Ljungman P, de La Camara R, Tridello G, et al
    Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European He
    Leukemia. 2021 Nov 8. pii: 10.1038/s41375-021-01466.

  461. GADI D, Griffith A, Tyekucheva S, Wang Z, et al
    A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
    Leukemia. 2021 Nov 6. pii: 10.1038/s41375-021-01441.
    PubMed     Abstract available

  462. CATHELIN S, Sharon D, Subedi A, Cojocari D, et al
    Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
    Leukemia. 2021 Nov 6. pii: 10.1038/s41375-021-01468.

  463. YANG M, Pan Z, Huang K, Busche G, et al
    A unique role of p53 haploinsufficiency or loss in the development of acute myeloid leukemia with FLT3-ITD mutation.
    Leukemia. 2021 Nov 3. pii: 10.1038/s41375-021-01452.
    PubMed     Abstract available

  464. KLOOS A, Mintzas K, Winckler L, Gabdoulline R, et al
    Correction: Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
    Leukemia. 2021 Nov 2. pii: 10.1038/s41375-021-01459.

  465. BURKE MJ, Devidas M, Chen Z, Salzer WL, et al
    Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232.
    Leukemia. 2021 Nov 1. pii: 10.1038/s41375-021-01460.
    PubMed     Abstract available

  466. BRUFORD EA, Antonescu CR, Carroll AJ, Chinnaiyan A, et al
    HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions.
    Leukemia. 2021;35:3040-3043.
    PubMed     Abstract available

  467. GALE RP, Hochhaus A, Cross NCP, Harrison CJ, et al
    HGNC nomenclature for fusion genes.
    Leukemia. 2021;35:3039.

  468. HU F, Wang Y, Wang WD, Gale RP, et al
    Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models.
    Leukemia. 2021;35:3073-3077.

  469. FERRER G, Jung B, Chiu PY, Aslam R, et al
    Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.
    Leukemia. 2021;35:3163-3175.
    PubMed     Abstract available

  470. FURMAN RR, Byrd JC, Owen RG, O'Brien SM, et al
    Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
    Leukemia. 2021;35:3201-3211.
    PubMed     Abstract available

  471. FALINI B, Sciabolacci S, Falini L, Brunetti L, et al
    Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field.
    Leukemia. 2021;35:3113-3126.
    PubMed     Abstract available

  472. HIRABAYASHI S, Butler ER, Ohki K, Kiyokawa N, et al
    Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group.
    Leukemia. 2021;35:3272-3277.

  473. DECKER M, Lammens T, Ferster A, Erlacher M, et al
    Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies.
    Leukemia. 2021;35:3304-3308.

    October 2021
  474. HEGDE S, Gasilina A, Wunderlich M, Lin Y, et al
    Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.
    Leukemia. 2021 Oct 28. pii: 10.1038/s41375-021-01455.
    PubMed     Abstract available

  475. VAN DIJK AD, Griffen TL, Qiu YH, Hoff FW, et al
    RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences.
    Leukemia. 2021 Oct 8. pii: 10.1038/s41375-021-01438.
    PubMed     Abstract available

  476. STETSON LC, Balasubramanian D, Ribeiro SP, Stefan T, et al
    Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression.
    Leukemia. 2021;35:2799-2812.
    PubMed     Abstract available

  477. GOURVEST M, De Clara E, Wu HC, Touriol C, et al
    A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
    Leukemia. 2021;35:2784-2798.
    PubMed     Abstract available

  478. LEWIS R, Maurer HC, Singh N, Gonzalez-Menendez I, et al
    CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
    Leukemia. 2021;35:2895-2905.
    PubMed     Abstract available

  479. RUPPERT AS, Booth AM, Ding W, Bartlett NL, et al
    Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
    Leukemia. 2021;35:2854-2861.
    PubMed     Abstract available

  480. SONG T, Guo Y, Xue Z, Guo Z, et al
    Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.
    Leukemia. 2021;35:2862-2874.
    PubMed     Abstract available

    September 2021
  481. BLIXT L, Bogdanovic G, Buggert M, Gao Y, et al
    Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
    Leukemia. 2021 Sep 25. pii: 10.1038/s41375-021-01424.
    PubMed     Abstract available

  482. SUD A, Law PJ, Houlston RS
    The clinical utility of polygenic risk scores for chronic lymphocytic leukemia.
    Leukemia. 2021 Sep 25. pii: 10.1038/s41375-021-01429.

  483. PAGOVICH OE, Stiles KM, Camilleri AE, Russo AR, et al
    Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS).
    Leukemia. 2021 Sep 20. pii: 10.1038/s41375-021-01400.
    PubMed     Abstract available

  484. JAKOBCZYK H, Jiang Y, Debaize L, Soubise B, et al
    ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis.
    Leukemia. 2021 Sep 17. pii: 10.1038/s41375-021-01409.

  485. TOKSVANG LN, Grell K, Nielsen SN, Nersting J, et al
    DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia.
    Leukemia. 2021 Sep 17. pii: 10.1038/s41375-021-01420.

  486. BOUCHER AC, Caldwell KJ, Crispino JD, Flerlage JE, et al
    Clinical and biological aspects of myeloid leukemia in Down syndrome.
    Leukemia. 2021 Sep 13. pii: 10.1038/s41375-021-01414.
    PubMed     Abstract available

  487. TAMAKI K, Morishima S, Suzuki S, Shigenari A, et al
    Full-length HLA sequencing in adult T cell leukemia-lymphoma uncovers multiple gene alterations.
    Leukemia. 2021 Sep 13. pii: 10.1038/s41375-021-01403.

  488. ECKARDT JN, Middeke JM, Riechert S, Schmittmann T, et al
    Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears.
    Leukemia. 2021 Sep 8. pii: 10.1038/s41375-021-01408.
    PubMed     Abstract available

  489. SAYGIN C, Hu E, Zhang P, Sher S, et al
    Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
    Leukemia. 2021 Sep 3. pii: 10.1038/s41375-021-01398.

  490. TAGA T, Tanaka S, Hasegawa D, Terui K, et al
    Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.
    Leukemia. 2021 Sep 1. pii: 10.1038/s41375-021-01397.

  491. ZHAO LP, Schell B, Sebert M, Kim R, et al
    Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease.
    Leukemia. 2021;35:2731-2733.

  492. ISSA GC, Ravandi F, DiNardo CD, Jabbour E, et al
    Therapeutic implications of menin inhibition in acute leukemias.
    Leukemia. 2021;35:2482-2495.
    PubMed     Abstract available

  493. GIONFRIDDO I, Brunetti L, Mezzasoma F, Milano F, et al
    Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML.
    Leukemia. 2021;35:2552-2562.
    PubMed     Abstract available

  494. HEYES E, Schmidt L, Manhart G, Eder T, et al
    Identification of gene targets of mutant C/EBPalpha reveals a critical role for MSI2 in CEBPA-mutated AML.
    Leukemia. 2021;35:2526-2538.
    PubMed     Abstract available

  495. ZHAO LP, Boy M, Azoulay C, Clappier E, et al
    Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease.
    Leukemia. 2021;35:2720-2724.

  496. ROLLIG C, Serve H, Noppeney R, Hanoun M, et al
    Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
    Leukemia. 2021;35:2517-2525.
    PubMed     Abstract available

  497. AL HINAI ASA, Grob T, Rijken M, Kavelaars FG, et al
    PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse.
    Leukemia. 2021;35:2693-2697.

  498. GODWIN CD, Laszlo GS, Fiorenza S, Garling EE, et al
    Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
    Leukemia. 2021;35:2496-2507.
    PubMed     Abstract available

    August 2021
  499. NIEDERKORN M, Ishikawa C, M Hueneman K, Bartram J, et al
    The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia.
    Leukemia. 2021 Aug 31. pii: 10.1038/s41375-021-01394.
    PubMed     Abstract available

  500. YUAN S, Wang X, Hou S, Guo T, et al
    PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression.
    Leukemia. 2021 Aug 31. pii: 10.1038/s41375-021-01392.
    PubMed     Abstract available

  501. RAFIQ S, McKenna SL, Muller S, Tschan MP, et al
    Lysosomes in acute myeloid leukemia: potential therapeutic targets?
    Leukemia. 2021 Aug 30. pii: 10.1038/s41375-021-01388.
    PubMed     Abstract available

  502. OZTURK S, Paul Y, Afzal S, Gil-Farina I, et al
    Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
    Leukemia. 2021 Aug 20. pii: 10.1038/s41375-021-01381.
    PubMed     Abstract available

  503. ZHANG XS, Gale RP, Huang XJ, Jiang Q, et al
    Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
    Leukemia. 2021 Aug 19. pii: 10.1038/s41375-021-01387.
    PubMed     Abstract available

  504. ANDRES-JENSEN L, Grell K, Rank CU, Albertsen BK, et al
    Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia.
    Leukemia. 2021 Aug 13. pii: 10.1038/s41375-021-01383.
    PubMed     Abstract available

  505. XU Y, Mou J, Wang Y, Zhou W, et al
    Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway.
    Leukemia. 2021 Aug 11. pii: 10.1038/s41375-021-01375.
    PubMed     Abstract available

  506. YOSHINO S, Tanaka M, Sunami Y, Takahara T, et al
    Trib1 promotes the development of acute myeloid leukemia in a Ts1Cje mouse model of Down syndrome.
    Leukemia. 2021 Aug 11. pii: 10.1038/s41375-021-01384.

  507. TADMOR T, Benjamini O, Braester A, Rahav G, et al
    Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
    Leukemia. 2021 Aug 10. pii: 10.1038/s41375-021-01380.

  508. LIU Q, Chan AKN, Chang WH, Yang L, et al
    3-Ketodihydrosphingosine reductase maintains ER homeostasis and unfolded protein response in leukemia.
    Leukemia. 2021 Aug 9. pii: 10.1038/s41375-021-01378.
    PubMed     Abstract available

  509. YAMAUCHI T, Miyawaki K, Semba Y, Takahashi M, et al
    Targeting leukemia-specific dependence on the de novo purine synthesis pathway.
    Leukemia. 2021 Aug 3. pii: 10.1038/s41375-021-01369.
    PubMed     Abstract available

  510. PIKMAN Y, Ocasio-Martinez N, Alexe G, Dimitrov B, et al
    Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.
    Leukemia. 2021 Aug 2. pii: 10.1038/s41375-021-01361.
    PubMed     Abstract available

  511. BACCARANI M, Gale RP
    Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.
    Leukemia. 2021;35:2199-2204.

  512. POLIVKOVA V, Benesova A, Zizkova H, Koblihova J, et al
    Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells.
    Leukemia. 2021;35:2419-2423.

  513. RICHTER J, Lubking A, Soderlund S, Lotfi K, et al
    Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
    Leukemia. 2021;35:2416-2418.

  514. RACA G, Abdel-Azim H, Yue F, Broach J, et al
    Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children-a novel health disparity.
    Leukemia. 2021;35:2399-2402.

  515. ABDULLA H, Vo A, Shields BJ, Davies TJ, et al
    T-ALL can evolve to oncogene independence.
    Leukemia. 2021;35:2205-2219.
    PubMed     Abstract available

  516. GUILHOT F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, et al
    Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
    Leukemia. 2021;35:2332-2345.
    PubMed     Abstract available

  517. FANG X, Xu S, Zhang Y, Xu J, et al
    Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish.
    Leukemia. 2021;35:2299-2310.
    PubMed     Abstract available

  518. TODISCO G, Creignou M, Galli A, Guglielmelli P, et al
    Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2(P95)-mutated neoplasms.
    Leukemia. 2021;35:2371-2381.
    PubMed     Abstract available

    July 2021
  519. RUCKER FG, Du L, Luck TJ, Benner A, et al
    Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
    Leukemia. 2021 Jul 28. pii: 10.1038/s41375-021-01323.
    PubMed     Abstract available

  520. ZHAO XY, Xu ZL, Mo XD, Chen YH, et al
    Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01351.

  521. KLEINSTERN G, Weinberg JB, Parikh SA, Braggio E, et al
    Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01344.
    PubMed     Abstract available

  522. VAN DER WERF I, Wojtuszkiewicz A, Yao H, Sciarrillo R, et al
    Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
    Leukemia. 2021 Jul 8. pii: 10.1038/s41375-021-01340.

  523. BOER JM, Valsecchi MG, Hormann FM, Antic Z, et al
    Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study.
    Leukemia. 2021 Jul 1. pii: 10.1038/s41375-021-01333.

  524. MARTELLI AM, Evangelisti C, Paganelli F, Chiarini F, et al
    GSK-3: a multifaceted player in acute leukemias.
    Leukemia. 2021;35:1829-1842.
    PubMed     Abstract available

  525. SEKERES MA, Watts J, Radinoff A, Sangerman MA, et al
    Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
    Leukemia. 2021;35:2119-2124.

  526. MODVIG S, Hallbook H, Madsen HO, Siitonen S, et al
    Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.
    Leukemia. 2021;35:1894-1906.
    PubMed     Abstract available

  527. ESTRUCH M, Reckzeh K, Vittori C, Centio A, et al
    Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.
    Leukemia. 2021;35:2030-2042.
    PubMed     Abstract available

  528. LIU H, Xuan L, Lin R, Deng L, et al
    A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study.
    Leukemia. 2021;35:2054-2063.
    PubMed     Abstract available

  529. TOMII T, Imamura T, Tanaka K, Kato I, et al
    Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model.
    Leukemia. 2021;35:2092-2096.

  530. RUMMELT C, Gorantla SP, Meggendorfer M, Charlet A, et al
    Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
    Leukemia. 2021;35:2017-2029.
    PubMed     Abstract available

  531. NAMBURI S, Broxmeyer HE, Hong CS, Whiteside TL, et al
    DPP4(+) exosomes in AML patients' plasma suppress proliferation of hematopoietic progenitor cells.
    Leukemia. 2021;35:1925-1932.
    PubMed     Abstract available

    June 2021
  532. SIMONETTI G, Mengucci C, Padella A, Fonzi E, et al
    Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
    Leukemia. 2021 Jun 30. pii: 10.1038/s41375-021-01318.
    PubMed     Abstract available

  533. THOMAS KR, Allenspach EJ, Camp ND, Wray-Dutra MN, et al
    Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
    Leukemia. 2021 Jun 30. pii: 10.1038/s41375-021-01326.
    PubMed     Abstract available

  534. TAJ MM, Moorman AV, Hamadeh L, Petit A, et al
    Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols.
    Leukemia. 2021 Jun 28. pii: 10.1038/s41375-021-01334.

  535. BEHNERT A, Meyer J, Parsa JY, Hechmer A, et al
    Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples.
    Leukemia. 2021 Jun 28. pii: 10.1038/s41375-021-01331.

  536. RENNEVILLE A, Patnaik MM, Chan O, Padron E, et al
    Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
    Leukemia. 2021 Jun 26. pii: 10.1038/s41375-021-01330.
    PubMed     Abstract available

  537. TOKSVANG LN, Grell K, Nersting J, Degn M, et al
    DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
    Leukemia. 2021 Jun 26. pii: 10.1038/s41375-021-01182.
    PubMed     Abstract available

  538. SHORT NJ, Kantarjian H, Jabbour E
    Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
    Leukemia. 2021 Jun 25. pii: 10.1038/s41375-021-01277.
    PubMed     Abstract available

  539. WIERDA WG, Rawstron A, Cymbalista F, Badoux X, et al
    Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
    Leukemia. 2021 Jun 24. pii: 10.1038/s41375-021-01241.
    PubMed     Abstract available

  540. ABDALLAH MG, Niibori-Nambu A, Morii M, Yokomizo T, et al
    RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner.
    Leukemia. 2021 Jun 19. pii: 10.1038/s41375-021-01268.

  541. NISHIDA Y, Zhao R, Heese LE, Akiyama H, et al
    Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
    Leukemia. 2021 Jun 14. pii: 10.1038/s41375-021-01308.
    PubMed     Abstract available

  542. LI Z, Jiang N, Lim EH, Chin WHN, et al
    Role of transcriptome sequencing in clinical diagnosis of B-cell acute lymphoblastic leukemia.
    Leukemia. 2021 Jun 10. pii: 10.1038/s41375-021-01185.

  543. KANTARJIAN HM, Hughes TP, Larson RA, Kim DW, et al
    Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
    Leukemia. 2021 Jun 9. pii: 10.1038/s41375-021-01306.

  544. DHAKAL B, Patel S, Girnius S, Bachegowda L, et al
    Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
    Leukemia. 2021 Jun 5. pii: 10.1038/s41375-021-01304.

  545. WIEDUWILT MJ, Stock W, Advani A, Luger S, et al
    Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: an
    Leukemia. 2021 Jun 4. pii: 10.1038/s41375-021-01303.

  546. KIM D, Park G, Huuhtanen J, Ghimire B, et al
    STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation.
    Leukemia. 2021 Jun 1. pii: 10.1038/s41375-021-01296.
    PubMed     Abstract available

  547. MAYANSKIY N, Luchkina P, Fedorova N, Lebedin Y, et al
    Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients.
    Leukemia. 2021;35:1820-1822.

  548. GURNARI C, Durrani J, Pagliuca S, Kishtagari A, et al
    Novel invariant features of Good syndrome.
    Leukemia. 2021;35:1792-1796.

  549. ARVINDAM US, van Hauten PMM, Schirm D, Schaap N, et al
    A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Leukemia. 2021;35:1586-1596.
    PubMed     Abstract available

  550. MARTINEZ-CUADRON D, Serrano J, Gil C, Tormo M, et al
    Evolving treatment patterns and outcomes in older patients (>/=60 years) with AML: changing everything to change nothing?
    Leukemia. 2021;35:1571-1585.
    PubMed     Abstract available

  551. ZHANG C, Wang XQ, Zhang RL, Liu F, et al
    Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.
    Leukemia. 2021;35:1563-1570.
    PubMed     Abstract available

  552. MURRAY HC, Enjeti AK, Kahl RGS, Flanagan HM, et al
    Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia.
    Leukemia. 2021;35:1782-1787.

  553. DE HAAS V, Pieters R, van der Sluijs-Gelling AJ, Zwaan CM, et al
    Flowcytometric evaluation of cerebrospinal fluid in childhood ALL identifies CNS involvement better then conventional cytomorphology.
    Leukemia. 2021;35:1773-1776.

    May 2021
  554. SAYGIN C, Hu E, Zhang P, Sher S, et al
    Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
    Leukemia. 2021 May 21. pii: 10.1038/s41375-021-01295.
    PubMed     Abstract available

  555. VAN DER ZWET JCG, Buijs-Gladdines JGCAM, Cordo' V, Debets DO, et al
    MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
    Leukemia. 2021 May 18. pii: 10.1038/s41375-021-01291.
    PubMed     Abstract available

  556. JAIN N, Thompson P, Burger J, Ferrajoli A, et al
    Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Leukemia. 2021 May 18. pii: 10.1038/s41375-021-01280.
    PubMed     Abstract available

  557. BRECCIA M, Pregno P, Castagnetti F, Bonifacio M, et al
    Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01292.

  558. CARRATT SA, Braun TP, Coblentz C, Schonrock Z, et al
    Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01278.
    PubMed     Abstract available

  559. DOURTHE ME, Rabian F, Yakouben K, Chevillon F, et al
    Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01281.
    PubMed     Abstract available

  560. VAN DER WERF I, Wojtuszkiewicz A, Yao H, Sciarrillo R, et al
    SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
    Leukemia. 2021 May 17. pii: 10.1038/s41375-021-01273.

  561. ROEKER LE, Knorr DA, Thompson MC, Nivar M, et al
    COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
    Leukemia. 2021 May 13. pii: 10.1038/s41375-021-01270.

  562. HUGHES TP, Clementino NCD, Fominykh M, Lipton JH, et al
    Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
    Leukemia. 2021 May 12. pii: 10.1038/s41375-021-01260.
    PubMed     Abstract available

  563. YAMAGATA K, Shino M, Aikawa Y, Fujita S, et al
    Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia.
    Leukemia. 2021 May 9. pii: 10.1038/s41375-021-01244.
    PubMed     Abstract available

  564. BRAVO-NAVAS S, Yanez L, Romon I, Briz M, et al
    Map of ubiquitin-like post-translational modifications in chronic lymphocytic leukemia. Role of p53 lysine 120 NEDDylation.
    Leukemia. 2021 May 8. pii: 10.1038/s41375-021-01184.

  565. STOMPER J, Rotondo JC, Greve G, Lubbert M, et al
    Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
    Leukemia. 2021 May 6. pii: 10.1038/s41375-021-01218.
    PubMed     Abstract available

  566. DAVER N, Alotaibi AS, Bucklein V, Subklewe M, et al
    T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
    Leukemia. 2021 May 5. pii: 10.1038/s41375-021-01253.
    PubMed     Abstract available

  567. GREVER M, Andritsos L, Banerji V, Barrientos JC, et al
    Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
    Leukemia. 2021 May 4. pii: 10.1038/s41375-021-01257.
    PubMed     Abstract available

    Prevention of childhood leukaemia by lifestyle changes.
    Leukemia. 2021;35:1265-1266.

  569. GREAVES M, Cazzaniga V, Ford A
    Can we prevent childhood Leukaemia?
    Leukemia. 2021;35:1258-1264.

  570. BERG JL, Perfler B, Hatzl S, Uhl B, et al
    EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity.
    Leukemia. 2021;35:1521-1526.

  571. LARGEAUD L, Cornillet-Lefebvre P, Hamel JF, Dumas PY, et al
    Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
    Leukemia. 2021;35:1291-1300.
    PubMed     Abstract available

    April 2021
  572. KIEHLMEIER S, Rafiee MR, Bakr A, Mika J, et al
    Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
    Leukemia. 2021 Apr 28. pii: 10.1038/s41375-021-01235.
    PubMed     Abstract available

  573. BHM JW, Sia KCS, Jones C, Evans K, et al
    Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
    Leukemia. 2021 Apr 24. pii: 10.1038/s41375-021-01248.
    PubMed     Abstract available

  574. GUNNARSSON R, Yang M, Olsson-Arvidsson L, Biloglav A, et al
    Single base substitution mutational signatures in pediatric acute myeloid leukemia based on whole genome sequencing.
    Leukemia. 2021 Apr 16. pii: 10.1038/s41375-021-01242.

  575. BROWN PA, Kairalla JA, Hilden JM, Dreyer ZE, et al
    Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
    Leukemia. 2021 Apr 12. pii: 10.1038/s41375-021-01245.

  576. CARRENO-TARRAGONA G, Varghese LN, Sebastian E, Galvez E, et al
    A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline.
    Leukemia. 2021 Apr 12. pii: 10.1038/s41375-021-01239.

  577. MONTALBAN-BRAVO G, Hammond D, DiNardo CD, Konopleva M, et al
    Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
    Leukemia. 2021 Apr 12. pii: 10.1038/s41375-021-01240.

  578. HSIEH YC, Kirschner K, Copland M
    Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01238.
    PubMed     Abstract available

  579. TAMBARO FP, Singh H, Jones E, Rytting M, et al
    Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01232.

  580. SCHLEISS C, Carapito R, Fornecker LM, Muller L, et al
    Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01221.
    PubMed     Abstract available

  581. BATTA K, Bossenbroek HM, Pemmaraju N, Wilks DP, et al
    Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.
    Leukemia. 2021 Apr 8. pii: 10.1038/s41375-021-01228.

  582. HU GH, Zhao XY, Zuo YX, Chang YJ, et al
    Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy.
    Leukemia. 2021 Apr 6. pii: 10.1038/s41375-021-01236.
    PubMed     Abstract available

  583. MILLER CR, Huang Y, Ruppert AS, Labanowska J, et al
    Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
    Leukemia. 2021 Apr 5. pii: 10.1038/s41375-021-01237.

  584. DAVIDS MS, Fisher DC, Tyekucheva S, McDonough M, et al
    A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
    Leukemia. 2021;35:1064-1072.
    PubMed     Abstract available

  585. REEDIJK AMJ, Coebergh JWW, de Groot-Kruseman HA, van der Sluis IM, et al
    Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015.
    Leukemia. 2021;35:1001-1011.
    PubMed     Abstract available

  586. LONTOS K, Yabes JG, Farah RJ, Boyiadzis M, et al
    Impact of upfront chemotherapy on overall survival in isolated myeloid sarcoma.
    Leukemia. 2021;35:1193-1196.

  587. AU YZ, Gu M, De Braekeleer E, Gozdecka M, et al
    KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.
    Leukemia. 2021;35:1012-1022.
    PubMed     Abstract available

    October 2020
  588. ZENT CS, Brady MT, Delage C, Strawderman M, et al
    Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
    Leukemia. 2020 Oct 30. pii: 10.1038/s41375-020-01074.

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.